UNITED STATES

SECURITIES and EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~December 31, 2016~~September 30, 2017

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-12537

QUALITY SYSTEMS, INC.

(Exact name of registrant as specified in its charter)



California (State or other jurisdiction of incorporation or organization) 18111 Von Karman Avenue, Suite 800, Irvine, California (Address of principal executive offices)	95-2888568 (IRS Employer Identification No.) 92612 (Zip Code)

(949) 255-2600 (Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated ~~filer” and~~filer,” “smaller reporting ~~company”~~company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.



Large accelerated filer þ	Accelerated filer o
Non-accelerated filer o (Do not check if a smaller reporting company)	Small reporting company o
	Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

The number of outstanding shares of the Registrant’s common stock as of ~~January 23,~~October 24, 2017 was ~~62,437,163~~63,671,536 shares.

QUALITY SYSTEMS, INC.

TABLE OF CONTENTS

FORM 10-Q

FOR THE THREE MONTHS ENDED ~~DECEMBER 31, 2016~~September 30, 2017



	Item	Page

	PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements.
	Unaudited Consolidated Balance Sheets as of ~~December 31, 2016~~September 30, 2017 and March 31, ~~2016~~2017	3
	Unaudited Consolidated Statements of Comprehensive Income for the three and ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and 2015~~	4
	Unaudited Consolidated Statements of Cash Flows for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and 2015~~	5
	Notes to Unaudited Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	21
Item 3.	Quantitative and Qualitative Disclosures about Market Risk.	3432
Item 4.	Controls and Procedures.	3432
	PART II. OTHER INFORMATION
Item 1.	Legal Proceedings.	3533
Item 1A.	Risk Factors.	3635
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	35
Item 3.	Defaults Upon Senior Securities.	35
Item 4.	Mine Safety Disclosure.	35
Item 5.	Other Information.	35
Item 6.	Exhibits.	36
~~Item 3.~~	~~Defaults Upon Senior Securities.~~	36Signatures
~~Item 4.~~	~~Mine Safety Disclosure.~~	36
~~Item 5.~~	~~Other Information.~~	36
~~Item 6.~~	~~Exhibits.~~	37
	~~Signatures~~	38

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

QUALITY SYSTEMS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

(Unaudited)


	December 31, 2016			March 31, 2016			September 30, 2017			March 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	23,994		$	27,176		$	26,553		$	37,673
Restricted cash and cash equivalents	4,647			5,320			6,488			4,916
Marketable securities	—			9,297
Accounts receivable, net	75,516			94,024			81,712			83,407
Inventory	252			555			147			158
Income taxes receivable	14,481			32,709			2,871			2,679
Prepaid expenses and other current assets	15,944			14,910			15,369			17,969
Total current assets	134,834			183,991			133,140			146,802
Equipment and improvements, net	26,097			25,790			27,681			27,426
Capitalized software costs, net	12,995			13,250			21,024			13,607
Deferred income taxes, net	9,780			8,198			10,289			11,265
Intangibles, net	74,722			91,675			86,746			69,213
Goodwill	185,888			188,837			216,530			185,898
Other assets	18,703			19,049			18,650			19,010
Total assets	$	463,019		$	530,790		$	514,060		$	473,221

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	5,223		$	11,126		$	6,813		$	4,618
Deferred revenue	49,763			57,935			52,285			52,383
Accrued compensation and related benefits	18,620			18,670			17,602			24,513
Income taxes payable	8			91			—			405
Other current liabilities	44,338			50,238			31,913			46,775
Total current liabilities	117,952			138,060			108,613			128,694
Deferred revenue, net of current	1,312			1,335			1,191			1,394
Deferred compensation	6,738			6,357			6,438			6,629
Line of credit	25,000			105,000			55,000			15,000
Other noncurrent liabilities	14,267			10,661			17,315			16,461
Total liabilities	165,269			261,413			188,557			168,178
Commitments and contingencies (Note 13)
Shareholders' equity:
Common stock
$0.01 par value; authorized 100,000 shares; issued and outstanding 62,437 and 60,978 shares at December 31, 2016 and March 31, 2016, respectively	624			610
$0.01 par value; authorized 100,000 shares; issued and outstanding 63,685 and 62,455 shares at September 30, 2017 and March 31, 2017, respectively							637			625
Additional paid-in capital	225,967			211,262			237,110			228,549
Accumulated other comprehensive loss	(653		)	(481		)	(457		)	(358		)
Retained earnings	71,812			57,986
Retained earnings ⁽¹⁾							88,213			76,227
Total shareholders' equity	297,750			269,377			325,503			305,043
Total liabilities and shareholders' equity	$	463,019		$	530,790		$	514,060		$	473,221

⁽¹⁾ Includes cumulative-effect adjustment related to the adoption of ASU 2016-09, as defined in Note 1. See Note 1 for additional details.

The accompanying notes are an integral part of these consolidated financial statements.

QUALITY SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except per share data)

(Unaudited)


	Three Months Ended December 31,						Nine Months Ended December 31,						Three Months Ended September 30,						Six Months Ended September 30,
	2016			2015			2016			2015			2017			2016			2017			2016
Revenues:
Software license and hardware	$	16,995		$	16,150		$	48,966		$	52,026		$	14,267		$	17,182		$	27,067		$	31,971
Software related subscription services	22,546			11,705			63,911			36,388			24,988			21,490			48,894			41,365
Total software, hardware and related	39,541			27,855			112,877			88,414			39,255			38,672			75,961			73,336
Support and maintenance	39,924			39,519			116,905			125,408			41,693			38,974			82,809			76,981
Revenue cycle management and related services	20,048			21,594			62,037			62,630			21,002			20,936			42,405			41,989
Electronic data interchange and data services	21,790			20,643			65,527			61,413			22,998			21,613			46,310			43,737
Professional services	6,565			7,421			19,893			26,700			7,659			6,971			16,044			13,328
Total revenues	127,868			117,032			377,239			364,565			132,607			127,166			263,529			249,371
Cost of revenue:
Software license and hardware	5,680			6,530			19,227			20,149			4,848			6,427			10,221			13,547
Software related subscription services	9,345			5,533			27,107			17,454			10,699			8,675			21,129			17,762
Total software, hardware and related	15,025			12,063			46,334			37,603			15,547			15,102			31,350			31,309
Support and maintenance	7,299			7,537			20,903			23,874			7,435			7,036			15,058			13,604
Revenue cycle management and related services	13,462			14,381			42,052			43,573			14,853			14,359			30,214			28,590
Electronic data interchange and data services	12,662			12,437			38,232			37,302			13,574			12,807			26,732			25,570
Professional services	5,904			7,367			19,643			24,008			7,346			6,693			14,570			13,739
Total cost of revenue	54,352			53,785			167,164			166,360			58,755			55,997			117,924			112,812
Gross profit	73,516			63,247			210,075			198,205			73,852			71,169			145,605			136,559
Operating expenses:
Selling, general and administrative	37,542			39,395			120,913			115,962			40,977			42,790			83,954			83,371
Research and development costs, net	19,714			14,518			56,230			49,584			19,527			18,292			39,516			36,516
Amortization of acquired intangible assets	2,568			897			7,889			2,692			2,012			2,617			4,059			5,321
Restructuring costs	231			—			4,685			—			—			701			—			4,454
Total operating expenses	60,055			54,810			189,717			168,238			62,516			64,400			127,529			129,662
Income from operations	13,461			8,437			20,358			29,967			11,336			6,769			18,076			6,897
Interest income	—			60			9			406			12			1			21			9
Interest expense	(629		)	(11		)	(2,445		)	(14		)	(840		)	(803		)	(1,517		)	(1,816		)
Other expense, net	(4		)	(43		)	(146		)	(147		)
Other income (expense), net													15			(55		)	(7		)	(142		)
Income before provision for income taxes	12,828			8,443			17,776			30,212			10,523			5,912			16,573			4,948
Provision for income taxes	2,342			1,141			3,950			8,233			2,493			1,925			4,647			1,608
Net income	$	10,486		$	7,302		$	13,826		$	21,979		$	8,030		$	3,987		$	11,926		$	3,340
Other comprehensive income:
Foreign currency translation, net of tax	(89		)	(7		)	(182		)	(291		)	(85		)	29			(99		)	(93		)
Unrealized gain (loss) on marketable securities, net of tax	—			(29		)	10			(34		)
Unrealized gain on marketable securities, net of tax													—			—			—			10
Comprehensive income	$	10,397		$	7,266		$	13,654		$	21,654		$	7,945		$	4,016		$	11,827		$	3,257
Net income per share:
Basic	$	0.17		$	0.12		$	0.22		$	0.36		$	0.13		$	0.06		$	0.19		$	0.05
Diluted	$	0.17		$	0.12		$	0.22		$	0.36		$	0.13		$	0.06		$	0.19		$	0.05
Weighted-average shares outstanding:
Basic	62,093			60,867			61,645			60,548			63,513			61,658			63,077			61,420
Diluted	62,093			61,279			61,900			61,190			63,530			62,052			63,089			61,704
Dividends declared per common share	$	—		$	0.175		$	—		$	0.525

The accompanying notes are an integral part of these consolidated financial statements.

QUALITY SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Nine Months Ended December 31,						Six Months Ended September 30,
	2016			2015			2017			2016
Cash flows from operating activities:
Net income	$	13,826		$	21,979		$	11,926		$	3,340
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	7,562			6,577			5,374			5,106
Amortization of capitalized software costs	6,626			7,428			2,571			4,819
Amortization of other intangibles	16,953			5,402			11,267			11,378
Amortization of debt issuance costs	807			—			538			538
Loss on disposal of equipment and improvements	452			158			45			175
Provision for bad debts	2,503			2,107			3,868			1,969
Provision for inventory obsolescence	369			118			36			224
Share-based compensation	5,177			2,328			5,132			3,177
Deferred income taxes	1,367			741			18			180
Excess tax deficiency from share-based compensation							346			—
Change in fair value of contingent consideration	3,797			1,201			—			5,830
Loss on disposition of Hospital Solutions Division	—			1,366
Changes in assets and liabilities:
Restructuring costs							—			701
Changes in assets and liabilities, net of amounts acquired:
Accounts receivable	16,005			11,313			(120		)	13,649
Inventory	(66		)	(160		)	(25		)	(22		)
Accounts payable	(5,983		)	6			1,323			(5,834		)
Deferred revenue	(8,195		)	(10,320		)	(929		)	(5,572		)
Accrued compensation and related benefits	(50		)	(7,706		)	(7,302		)	(4,179		)
Income taxes	18,060			(18,395		)	(348		)	17,213
Deferred compensation	381			917			(191		)	437
Other assets and liabilities	1,832			2,232			4,565			3,256
Net cash provided by operating activities	81,423			27,292			38,094			56,385
Cash flows from investing activities:
Additions to capitalized software costs	(6,371		)	(11,604		)	(9,624		)	(5,319		)
Additions to equipment and improvements	(8,242		)	(9,926		)	(5,423		)	(4,989		)
Proceeds from sales and maturities of marketable securities	9,291			5,310			—			9,291
Purchases of marketable securities	—			(6,024		)
HealthFusion working capital adjustment payment	(282		)	—
Payments for acquisitions, net of cash acquired							(58,892		)	—
Net cash used in investing activities	(5,604		)	(22,244		)	(73,939		)	(1,017		)
Cash flows from financing activities:
Proceeds from line of credit							50,000			—
Principal repayments on line of credit	(80,000		)	—			(10,000		)	(57,000		)
Payment of contingent consideration related to acquisitions							(18,817		)	—
Proceeds from issuance of shares under employee plans	999			732			4,320			702
Dividends paid	—			(32,125		)
Net cash used in financing activities	(79,001		)	(31,393		)
Net increase decrease in cash and cash equivalents	(3,182		)	(26,345		)
Cancellation of shares related to tax withholdings for vesting of equity awards							(778		)	—
Net cash provided by (used in) financing activities							24,725			(56,298		)
Net decrease in cash and cash equivalents							(11,120		)	(930		)
Cash and cash equivalents at beginning of period	27,176			118,993			37,673			27,176
Cash and cash equivalents at end of period	$	23,994		$	92,648		$	26,553		$	26,246

QUALITY SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS – (Continued)

(In thousands)

(Unaudited)


	Nine Months Ended December 31,				Six Months Ended September 30,
	2016		2015		2017		2016
Supplemental disclosures of cash flow information:
Cash paid for income taxes	$	4,455	$	27,653	$	5,396	$	3,977
Cash refunds from income taxes	$	19,932	$	2,079	713		19,762
Cash paid for interest	$	1,670	$	—	933		1,443
Common stock issued for Mirth share-based contingent consideration	$	9,273	$	9,273
Non-cash investing and financing activities:
Tenant improvement allowance from landlord	$	3,094	$	1,324	$	1,442	$	3,094
Dividends declared but not paid	$	—	$	10,726
Unpaid additions to equipment and improvements	$	80	$	226	117		488



On April 14, 2017, we acquired Entrada in a transaction summarized as follows:
Fair value of net assets acquired	$	35,293		$	—
Cash paid, net of cash acquired	(33,856		)	—
Liabilities assumed	$	1,437		$	—



On August 16, 2017, we acquired EagleDream in a transaction summarized as follows:
Fair value of net assets acquired	$	27,895		$	—
Cash paid, net of cash acquired	(25,036		)	—
Liabilities assumed	$	2,859		$	—

The accompanying notes are an integral part of these consolidated financial statements.

QUALITY SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except shares and per share data)

(Unaudited)

1. Summary of Significant Accounting Policies

Principles of Consolidation. The consolidated financial statements include the accounts of Quality Systems, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Each of the terms “we,” “us,” or “our” as used herein refers collectively to the Company, unless otherwise stated. All intercompany accounts and transactions have been eliminated.

Business Segments. We have determined that the Company operates in one segment as of June 30, 2017. We have made such determination by first identifying our Chief Executive Officer as our chief operating decision maker ("CODM") and considering the measures used by our CODM to allocate resources. Our CODM utilizes consolidated revenue and consolidated operating results to assess performance and make decisions about allocation of resources.

Previously, through the end of fiscal year 2017, we operated under two reportable segments, consisting of the Software and Related Solutions segment and the RCM and Related Services segment, which was consistent with the disaggregated financial information used and evaluated by our CODM to assess performance and make decisions about the allocation of resources. However, as part of our reorganization efforts that were substantially complete as of the end of fiscal year 2017, our internal organizational structure whereby certain functions that formerly existed within each individual operating segment has continued to evolve. Our former Chief Operating Officer was previously responsible for leading the operations of our former RCM and Related Services business while our former Chief Client Officer led our client success organization, consisting of the Software and Related Solutions business and other functions, such as sales and marketing. Upon the resignation of our former Chief Operating Officer in April 2017 and concurrent appointment of our former Chief Client Officer as Chief Operating Officer, our entire portfolio of software and services were aligned under our new Chief Operating Officer in an effort to provide our clients with an even more simplified experience and more effectively deliver a consolidated financial solution to our clients, rather than components of a solution. As a result of such changes in our internal organization structure, the CODM now operates the Company as a single functional organization. The CODM measures company-wide performance by reviewing consolidated revenue and operating results and evaluates the impact of allocating resources to overall profit and margins on a consolidated basis.

Basis of Presentation. The accompanying unaudited consolidated financial statements as of ~~December 31, 2016~~September 30, 2017 and for the three and ~~nine~~six months ended ~~December 31, 2016~~September 30, 2017 have been prepared in accordance with the requirements of Quarterly Report on Form 10-Q and Article 10 of the Securities and Exchange Commission Regulation S-X and therefore do not include all information and notes which would be presented were such consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in our Annual Report on Form 10-K for the fiscal year ended March 31, ~~2016.~~2017. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair statement of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year.

References to amounts in the consolidated financial statement sections are in thousands, except shares and per share data, unless otherwise specified.

Significant Accounting Policies. ~~Effective July 1, 2016, we revised our reportable operating segments (see Note 14).~~ There have been no ~~other~~ material changes to ~~the~~our significant accounting policies from those disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, ~~2016.~~2017.

Share-Based Compensation. The following table shows total share-based compensation expense included in the consolidated statements of comprehensive income for the three and ~~nine~~six months ended ~~December 31, 2016~~September 30, 2017 and ~~2015:~~2016:


	Three Months Ended December 31,						Nine Months Ended December 31,						Three Months Ended September 30,						Six Months Ended September 30,
	2016			2015			2016			2015			2017			2016			2017			2016
Costs and expenses:
Cost of revenue	$	144		$	101		$	459		$	300		$	290		$	166		$	427		$	315
Research and development costs, net	273			67			690			280			513			334			874			417
Selling, general and administrative	1,584			575			4,028			1,748			2,288			1,418			3,831			2,445
Total share-based compensation	2,001			743			5,177			2,328			3,091			1,918			5,132			3,177
Income tax benefit	(718		)	(225		)	(1,825		)	(701		)	(1,144		)	(695		)	(1,860		)	(1,107		)
Decrease in net income	$	1,283		$	518		$	3,352		$	1,627		$	1,947		$	1,223		$	3,272		$	2,070

Recent Accounting Standards. Recent accounting pronouncements requiring implementation in future periods are discussed below or in the notes, where applicable.

In May 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-09, Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting ("ASU 2017-09"). ASU 2017-09 clarifies the changes to terms or conditions of a share-based payment award that require an entity to apply modification accounting. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early application is permitted and prospective application is required. ASU 2017-09 is effective for us in the first quarter of fiscal 2019, and we currently do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles–Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). ASU 2017-04 removes the requirement to compare the implied fair value of goodwill with its carrying amount as part of Step two of the goodwill impairment test. Instead, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019, and early adoption is permitted on goodwill impairment tests performed on testing dates after January 1, 2017. ASU 2017-04 is effective for us in the fourth quarter of fiscal 2020, and we currently do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”). ASU 2017-01 clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted in two scenarios as identified in the new standard. ASU 2017-01 is effective for us in the first quarter of fiscal 2019, and we currently do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

In November 2016, the FASB issued Accounting Standards Update ("ASU") 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”). ASU 2016-18 provides guidance on the classification of restricted cash and cash equivalents in the statement of cash flows. Although it does not provide a definition of restricted cash or restricted cash equivalents, it states that amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. ASU 2016-18 is effective for us in the first quarter of fiscal 2019, and we do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

In October 2016, the FASB issued ASU 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory ("ASU 2016-16"). ASU 2016-16 requires the recognition of current and deferred income taxes for intra-entity asset transfers when the transaction occurs. ASU 2016-16 is effective for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. ASU 2016-16 is effective for us in the first quarter of fiscal 2019, and we are currently in the process of evaluating the potential impact of adoption of this updated authoritative guidance on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 is intended to add and clarify guidance on the classification of certain cash receipts and cash payments in the statement of cash flows to eliminate diversity in practice related to how such cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. ASU 2016-15 is effective for us in the first quarter of fiscal 2019, and we do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). ASU 2016-09 simplifies the accounting for and reporting on share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for interim and annual reporting periods beginning after December 15, 2016, with early adoption permitted. The amendments in this update are to be applied differently upon adoption with certain amendments being applied prospectively, retrospectively and under a modified retrospective transition method. We ~~expect to adopt~~adopted ASU 2016-09 in the first quarter of fiscal ~~2018,~~2018. As permitted by ASU 2016-09, we have made an accounting policy election to account for forfeitures as they occur, which was adopted on a modified retrospective basis and ~~we do~~resulted in a cumulative-effect adjustment of $0.1 million to retained earnings and additional paid-in capital as of April 1, 2017. ASU 2016-09 also eliminates additional paid-in capital pools and requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled, which was adopted on a prospective basis. The requirements to recognize previously unrecognized excess tax benefits on a modified retrospective basis did not ~~expect the adoption of this new standard to~~ have ~~a material~~an impact on our consolidated financial statements. Upon adoption of ASU 2016-09, excess tax benefits and tax deficiencies are recognized in the income statement, and the tax effects of exercised or vested awards are treated as discrete items in the period they occur. The provisions of ASU 2016-09 could have an impact to our future income tax expense, including increased volatility in our effective tax rate on a quarter by quarter basis due to a number of factors, including fluctuations in the stock price and the timing of stock option exercises and vesting of restricted share

awards. Additionally, ASU 2016-09 addresses presentation of excess tax benefits and deficiencies and employee taxes paid related to shares withheld for tax withholdings purposes on the statement of cash flows, including a requirement to present excess tax benefits and deficiencies as an operating activity in the same manner as other cash flows related to income taxes on the statement of cash flows, which will be adopted on a prospective basis, and presentation of employee taxes paid related to shares withheld for tax withholdings purposes as a financing activity, which is consistent with our current presentation and thus did not impact our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”), which is intended to improve financial reporting about leasing transactions. The new guidance will require lessees to recognize on their balance sheets the assets and liabilities for the rights and obligations created by leases and to disclose key information about the leasing arrangements. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. ASU 2016-02 is effective for us in the first quarter of fiscal 2020. We are currently in the process of evaluating the potential impact of adoption of this updated authoritative guidance on our consolidated financial statements.

~~In April 2015, the FASB issued ASU 2015-05,~~ ~~Customer’s Accounting for Fees Paid in a Cloud Arrangement~~ ("ASU 2015-05"), which requires a customer to determine whether a cloud computing arrangement contains a software license that should be accounted for as internal-use software or as a service contract. ASU 2015-05 is effective for interim and annual reporting periods beginning after December 15, 2015, with early adoption permitted. Upon adoption, an entity has the option to apply the provisions of ASU 2015-05 either prospectively to all arrangements entered into or materially modified, or retrospectively. The adoption of this new standard did not have material impact on our consolidated financial statements.

~~In August 2014, the FASB issued ASU 2014-15,~~ ~~Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern~~ ("ASU 2014-15"), which incorporates and expands upon certain principles that currently exist in U.S. auditing standards. ASU 2014-15 provides guidance regarding management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. The new standard requires management to perform interim and annual evaluations and sets forth principles for considering the mitigating effect of management's plans. The standard mandates certain disclosures when conditions give rise to substantial doubt about a company’s ability to continue as a going concern within one year from the financial statement issuance date. ASU 2014-15 is effective for us commencing fiscal year ending March 31, 2017. The adoption of this new standard has not had, and is not expected to have, an impact on our consolidated financial statements.

In May 2014, the FASB, along with the International Accounting Standards Board, issued ASU 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards and GAAP. The core principle of this updated guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new standard also requires additional disclosure about revenue and provides improved guidance for multiple element arrangements. In July 2015 decision, the FASB issued ASU 2015-14, Deferral of Effective Date ("ASU 2015-14") to delay the effective date by one year. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606) –Principal versus Agent Consideration ("ASU 2016-08"). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing ("ASU 2016-10”). In May 2016, the FASB issued ASU 2016-11, Revenue from Contracts with Customers (Topic 606) and Derivatives and Hedging (Topic 815) – Rescission of SEC Guidance Because of ASU 2014-09 and 2014-16 ("ASU 2016-11") and ASU 2016-12, Revenue from Contracts with Customers (Topic 606) –Narrow Scope Improvements and Practical Expedients ("ASU 2016-12"). The new ASUs do not change the core principle of the guidance in Topic 606 (as amended by ASU 2014-09), but rather help to provide further interpretive clarifications on the new guidance in ASU 2014-09. ASU 2014-09, as amended by ASU 2015-14, is effective for us in the first quarter of fiscal 2019. Companies are permitted to adopt this new guidance following either a full retrospective or modified retrospective approach.

We have ~~established a cross-functional team to assess~~completed our assessment of the potential impact of the new revenue standard. Our assessment process consists of reviewing our current accounting policies and practices to identify potential differences that would result from applying the requirements of the new standard to our revenue contracts and identifying appropriate changesimpacts to our business processes, systems, and internal controls ~~to support revenue recognition and disclosure requirements under~~that could result from the implementation of the new ~~standard. Our initial~~revenue guidance. Based on our assessment, we currently believe that the impact on our consolidated financial statements could be material. We expect that revenue related to hardware, EDI, maintenance, and certain subscriptions would remain substantially unchanged, and we are the process of evaluating the impact of the new revenue ~~standard~~guidance on our other revenue streams. Due to the complexity of our revenue recognition, a significant amount of work remains as we continue to evaluate all potential impacts of the new revenue guidance, and develop and implement the necessary changes to our current ~~business~~accounting systems, processes, ~~systems~~ and ~~controls~~internal controls. Accordingly, our preliminary assessments are ~~expected~~subject to change. We expect that the new revenue guidance will result in additional complexity to our revenue recognition, including the use of an increased amount of significant judgments and estimates, particularly as it relates to our RCM services revenue, as compared to our current revenue recognition.

Additionally, certain incremental costs incurred to obtain contracts with customers, such as sales commissions, are within the scope of the new revenue guidance and are required to be ~~completed during fiscal 2017. Additionally,~~capitalized and amortized to expense over the remaining performance periods of the contracts. Currently, our sales commission are capitalized and amortized to expense over the related period of revenue recognition. Although the amortization period of capitalized sales commissions may differ upon adoption of the new revenue guidance, we ~~are currently evaluating~~do not expect the ~~potential impact that the implementation~~adoption of this new revenue

standard ~~will~~to have a material impact on our consolidated financial statements ~~as well as selection~~with respect to the capitalization and amortization of ~~the method of adoption.~~ sales commissions.

We currently ~~do not~~ expect to implement the new revenue guidance when it becomes effective for us in the first quarter of fiscal 2019 utilizing the modified retrospective transition method. Under this transition method, prior period amounts will not be adjusted and the cumulative effect from prior periods of applying the new ~~standard prior~~revenue guidance will be recognized in our consolidated balance sheets as of the date of adoption, including an adjustment to ~~the required effective date.~~retained earnings.

We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

2. Fair Value Measurements

The following tables set forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis at ~~December 31, 2016~~September 30, 2017 and March 31, ~~2016:~~2017:


	Balance at		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)		Balance at			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)
	December 31, 2016				September 30, 2017												Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)
ASSETS
Cash and cash equivalents⁽¹⁾	$	23,994	$	23,994		Significant Other Observable Inputs (Level 2)	$	—	Unobservable Inputs (Level 3)		$	—	$	26,553		$	26,553		$	—		$	—
Restricted cash and cash equivalents	4,647		4,647			—			—		6,488			6,488			—			—
	$	28,641	$	28,641		$	—		$	—	$	33,041		$	33,041		$	—		$	—
LIABILITIES
Contingent consideration related to acquisitions	$	18,367	$	—		$	18,367		$	—
	$	18,367	$	—		$	18,367		$	—


	Balance at		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)		Balance at			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)
	March 31, 2016				March 31, 2017												Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)
ASSETS
Cash and cash equivalents ⁽¹⁾	$	27,176	$	27,176		Significant Other Observable Inputs (Level 2)	$	—	Unobservable Inputs (Level 3)		$	—	$	37,673		$	37,673		$	—		$	—
Restricted cash and cash equivalents	5,320		5,320			—			—		4,916			4,916			—			—
Marketable securities ⁽²⁾	9,297		9,297			—			—
	$	41,793	$	41,793		$	—		$	—	$	42,589		$	42,589		$	—		$	—
LIABILITIES
Contingent consideration related to acquisitions	$	23,843	$	—		$	—		$	23,843
Contingent consideration related to acquisitions ⁽²⁾											$	18,817		$	—		$	18,817		$	—
	$	23,843	$	—		$	—		$	23,843	$	18,817		$	—		$	18,817		$	—

⁽¹⁾ Cash equivalents consist primarily of money market funds.

⁽²⁾~~Marketable securities consist of available-for-sale money market instruments and fixed-income securities, including certificates of deposit, corporate bonds and notes, and municipal securities.~~

The contingent consideration liability as of ~~December~~March 31, ~~2016~~2017 relates to the acquisition of HealthFusion, ~~(see Note 3). Prior to December 31, 2016, we had assessed~~which was settled during the ~~fair value~~quarter ended June 30, 2017. The measurement period of the contingent consideration liability on a recurring basis and any adjustments to fair value subsequent to the measurement period were reflected in the consolidated statements of comprehensive income. Key assumptions included discount rates and probability-adjusted achievement estimates of certain revenue targets that were not observable in the market. The categorization of the framework used to measure fair value of the contingent consideration liability was previously considered to be within the Level 3 valuation hierarchy due to the subjective nature of the unobservable inputs used. As of the end of the measurement periodended on December 31, 2016, and thus the actual revenue achievement rate was utilized to compute the ending contingent consideration ~~liability.~~liability as of March 31, 2017. Accordingly, the contingent consideration liability was ~~transferred into the~~reflected under a Level 2 valuation hierarchy because the fair value was determined based on other significant observable inputs.

The following table presents activity in our financial assets and liabilities measured at fair value using significant unobservable inputs (Level 3), as of and for the nine months ended December 31, 2016:

Total Liabilities
Balance at April 1, 2016 $ 23,843
Settlement of contingent consideration related to Mirth (9,273 )
Fair value adjustments 3,797
Transfer of HealthFusion contingent consideration to Level 2 (18,367 )
Balance at December 31, 2016 $ —

During the nine months ended December 31, 2016, we issued shares of common stock to settle $9,273 in contingent consideration liabilities related to the acquisition of Mirth and recorded $3,797 of fair value adjustments to contingent consideration liabilities, of which $3,367 was related to HealthFusion and $430 was related to Mirth. During the three months ended December 31, 2016, we recorded a benefit of $2,033 for fair value adjustments of contingent consideration liabilities related to HealthFusion. The fair value adjustments to contingent consideration liabilities are included as a component of selling, general and administrative expense in the consolidated statements of comprehensive income.

We believe that the fair value of other financial assets and liabilities, including accounts receivable, accounts payable, and line of credit, approximate their respective carrying values due to their nominal credit risk.

Non-Recurring Fair Value Measurements

We have certain assets, including goodwill and other intangible assets, which are measured at fair value on a non-recurring basis and are adjusted to fair value only if an impairment charge is recognized. The categorization of the framework used to measure fair value of the assets is considered to be within the Level 3 valuation hierarchy due to the subjective nature of the unobservable inputs used. During the ~~nine~~three and six months ended ~~December 31, 2016, we recorded certain~~September 30, 2017, no adjustments ~~to HealthFusion goodwill (see Note 3).~~were recorded.

3. Business Combinations

~~HealthFusion~~Entrada Acquisition

On ~~January 4, 2016,~~April 14, 2017, we completed our acquisition of ~~HealthFusion Holdings,~~Entrada, Inc. ("~~HealthFusion"~~Entrada") pursuant to the terms of the Agreement and Plan of Merger, dated April 11, 2017 (the ~~“Merger Agreement"~~"Agreement")~~, dated October 30, 2015. HealthFusion provides Web-based, cloud computing software for physicians, medical billing service providers, and hospitals. Its flagship product, MediTouch®,~~. Based in Nashville, TN, Entrada is a ~~fully-integrated,~~leading provider of cloud-based ~~software suite consisting~~solutions that are reshaping the way care is delivered by leveraging the power of ~~clearinghouse, practice management,~~mobile whenever and wherever care happens. Entrada’s best-in-class mobile application integrates with multiple clinical platforms and all major electronic health ~~records,~~record systems. Entrada enables organizations to maximize their existing technology investments while simultaneously enhancing physician and ~~patient portals with rich functionality to enable mobility, workflow automation, and advanced reporting and analytics aimed primarily at small-to-mid-size physician practices.~~staff productivity. The acquisition of ~~HealthFusion~~Entrada and its cloud-based, mobile application is part of our ~~strategy~~commitment to ~~expand~~deliver systematic solutions that meet its ~~client base~~clients' transforming work requirements to become increasingly nimble and ~~cloud-based solution capabilities in the ambulatory market. Over time, we plan to expand the HealthFusion platform to satisfy the needs of practices of increasing size and complexity.~~mobile.

The preliminary purchase price ~~totals $183,049,~~totaled $33,958, which ~~includes~~included preliminary working capital and other customary adjustments and the fair value of contingent consideration related to an additional $25,000 of cash in the form of an earnout, subject to HealthFusion achieving certain revenue targets through December 31, 2016. The initial estimated fair value of contingent consideration of $16,700 was based on a Monte Carlo-based valuation model that considered, among other assumptions and inputs, our estimate of projected HealthFusion revenues. As of December 31, 2016, the fair value of the contingent consideration was $18,367.

adjustments. The acquisition was ~~initially~~primarily funded by a draw against ~~the~~our revolving credit agreement (see Note 7)~~, a portion of which was subsequently repaid from existing cash on hand.~~.

We accounted for the ~~HealthFusion~~Entrada acquisition as a purchase business combination using the acquisition method of accounting. The preliminary purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their preliminary estimated fair values as of the acquisition date. The preliminary fair values of acquired assets and liabilities assumed represent management’s estimate of fair value and are subject to change if additional information, such as changes to deferred

taxes and/or working capital, becomes available. We expect to finalize the purchase price allocation as soon as practicable within the measurement period, but not later than one year following the acquisition date.

The preliminary estimated fair value of the acquired tangible and intangible assets and liabilities assumed were determined using multiple valuation approaches depending on the type of tangible or intangible asset acquired, including but not limited to the income approach, the excess earnings method and the relief from royalty method approach.

In connection with the Entrada acquisition, we recorded $15,400 of intangible assets related to customer relationships, trade names and software technology. We are amortizing the Entrada customer relationships over 10 years and trade names and software technology over 5 years. The weighted average amortization period for the total amount of intangible assets acquired is 6.1 years.

The preliminary amount of goodwill represents the excess of the preliminary purchase price over the preliminary net identifiable assets acquired and liabilities assumed. Goodwill primarily represents, among other factors, the value of synergies expected to be realized and the assemblage of all assets that enable us to create new client relationships, neither of which qualify as separate amortizable intangible assets. Goodwill arising from the acquisition of Entrada is not deductible for tax purposes and is allocated to our single reportable segment.

The total preliminary purchase price for the Entrada acquisition is summarized as follows:



Initial purchase price	$	34,000
Preliminary working capital and other adjustments	(42		)
Total preliminary purchase price	$	33,958



	April 14, 2017
Preliminary fair value of the net tangible assets acquired and liabilities assumed:
Acquired cash and cash equivalents	$	102
Accounts receivable, net	1,835
Prepaid expense and other current assets	145
Equipment and improvements, net	134
Capitalized software costs, net	364
Deferred income taxes, net	1,041
Accounts payable	(639		)
Accrued compensation and related benefits	(120		)
Deferred revenues	(234		)
Other liabilities	(444		)
Total preliminary net tangible assets acquired and liabilities assumed	2,184
Preliminary fair value of identifiable intangible assets acquired:
Goodwill	16,374
Software technology	10,500
Customer relationships	3,300
Trade name	1,600
Total preliminary identifiable intangible assets acquired	31,774
Total preliminary purchase price	$	33,958

The pro forma effects of the Entrada acquisition would not have been material to the Company's results of operations and are therefore not presented.

EagleDream Health Acquisition

On August 16, 2017, we completed the acquisition of EagleDream Health, Inc. ("EagleDream") pursuant to the Agreement and Plan of Merger (the “Merger Agreement"), dated July 31, 2017. Headquartered in Rochester, NY, EagleDream is a cloud-based analytics company that drives meaningful insight across clinical, financial and administrative data to optimize practice performance.

The preliminary purchase price totaled $25,609, which included preliminary working capital and other customary adjustments. The acquisition was partially funded by a draw against our revolving credit agreement (see Note 7).

We accounted for the EagleDream acquisition as a purchase business combination using the acquisition method of accounting. The preliminary purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their

preliminary estimated fair values as of the acquisition date. The preliminary fair values of acquired assets and liabilities assumed represent management’s estimate of fair value and are subject to change if additional information, such as changes to deferred taxes and/or working capital, becomes available. We expect to finalize the purchase price allocation as soon as practicable within the measurement period, but not later than one year following the acquisition date.

In connection with the EagleDream acquisition, we recorded $13,400 of intangible assets related to customer relationships and software technology. We are amortizing the EagleDream customer relationships over 8 years and software technology over 5 years. The weighted average amortization period for the total amount of intangible assets acquired is 5.1 years.

realized and the assemblage of all assets that enable us to create new client relationships, neither of which qualify as separate amortizable intangible assets. Goodwill arising from the acquisition of ~~HealthFusion was determined as the excess of the preliminary purchase price over the net acquisition date fair values of the acquired assets and the liabilities assumed, and~~EagleDream is not deductible for tax ~~purposes. HealthFusion operates under~~purposes and is allocated to our ~~Software and Related Solutions~~single reportable segment. ~~During the nine months ended December 31, 2016, we recorded a $2,949 adjustment to HealthFusion goodwill related to changes in deferred taxes based on the filing of final tax returns.~~

The total preliminary purchase price for the ~~HealthFusion~~EagleDream acquisition is summarized as follows:

Initial purchase price $ 165,000
Contingent consideration 16,700
Preliminary working capital and other adjustments 1,349
Total preliminary purchase price $ 183,049

January 4, 2016
Preliminary fair value of the net tangible assets acquired and liabilities assumed:
Acquired cash and cash equivalents $ 2,225
Accounts receivable, net 1,514
Prepaid expenses and other current assets 4,645
Equipment and improvements, net 767
Capitalized software costs, net 307
Other assets 700
Accounts payable (1,085 )
Accrued compensation and related benefits (533 )
Deferred revenue (1,067 )
Deferred income taxes, net (9,078 )
Other liabilities (2,721 )
Total preliminary net tangible assets acquired and liabilities assumed (4,326 )
Preliminary fair value of identifiable intangible assets acquired:
Software technology 42,500
Customer relationships 28,500
Trade name 4,000
Goodwill 112,375
Total preliminary identifiable intangible assets acquired 187,375
Total preliminary purchase price $ 183,049



Initial purchase price	$	26,000
Preliminary working capital and other adjustments	(391		)
Total preliminary purchase price	$	25,609



	August 16, 2017
Preliminary fair value of the net tangible assets acquired and liabilities assumed:
Acquired cash and cash equivalents	$	573
Accounts receivable	217
Prepaid expense and other current assets	20
Accounts payable	(115		)
Accrued compensation and related benefits	(271		)
Deferred revenues	(394		)
Deferred income taxes, net	(1,957		)
Other liabilities	(122		)
Total preliminary net tangible assets acquired and liabilities assumed	(2,049		)
Preliminary fair value of identifiable intangible assets acquired:
Goodwill	14,258
Software technology	12,800
Customer relationships	600
Total preliminary identifiable intangible assets acquired	27,658
Total preliminary purchase price	$	25,609

The pro forma effects of the EagleDream acquisition would not have been material to the Company's results of operations and are therefore not presented.

4. Goodwill

We test goodwill for impairment annually during our first fiscal quarter, referred to as the annual test date. We will also test for impairment between annual test dates if an event occurs or circumstances change that would indicate the carrying amount may be impaired. We have not identified any events or circumstances as of ~~December 31, 2016~~September 30, 2017 that would require an interim goodwill impairment test. ~~During the nine months ended December 31, 2016, we recorded certain adjustment to HealthFusion goodwill (see Note 3).~~

We do not amortize goodwill as it has been determined to have an indefinite useful life.

~~We have also determined that the change in reportable operating segments as a result of our ongoing reorganization efforts (see Note 14) did not have a significant impact on the~~ The carrying amount of goodwill ~~that is allocated to each reporting unit~~as of September 30, 2017 was $216,530, which reflects the acquisitions of Entrada and ~~each reportable operating segment~~EagleDream (see Note 3). ~~Goodwill by reportable operating segment consists~~ The carrying amount of ~~the following:~~

December 31,
2016 March 31,
2016
Software and Related Solutions $ 153,598
$ 156,547
RCM and Related Services 32,290
32,290
Total goodwill $ 185,888
$ 188,837
goodwill as of March 31, 2017 was $185,898.

5. Intangible Assets

Our definite-lived intangible assets, other than capitalized software development costs, are summarized as ~~follows:~~follows, and reflects the acquisitions of Entrada and EagleDream (see Note 3):


	December 31, 2016												September 30, 2017
	Customer Relationships			Trade Name and Contracts			Software Technology			Total			Customer Relationships			Trade Name and Contracts			Software Technology			Total
Gross carrying amount	$	50,550		$	5,480		$	67,810		$	123,840		$	54,450		$	7,080		$	91,110		$	152,640
Accumulated amortization	(26,693		)	(1,821		)	(20,604		)	(49,118		)	(32,349		)	(2,770		)	(30,775		)	(65,894		)
Net intangible assets	$	23,857		$	3,659		$	47,206		$	74,722		$	22,101		$	4,310		$	60,335		$	86,746


	March 31, 2016												March 31, 2017
	Customer Relationships			Trade Name and Contracts			Software Technology			Total			Customer Relationships			Trade Name and Contracts			Software Technology			Total
Gross carrying amount	$	50,550		$	7,368		$	67,810		$	125,728		$	50,550		$	5,480		$	67,810		$	123,840
Accumulated amortization	(19,618		)	(2,895		)	(11,540		)	(34,053		)	(28,972		)	(2,088		)	(23,567		)	(54,627		)
Net intangible assets	$	30,932		$	4,473		$	56,270		$	91,675		$	21,578		$	3,392		$	44,243		$	69,213

Amortization expense related to customer relationships and trade name and contracts recorded as operating expenses in the consolidated statements of comprehensive income was ~~$2,568~~$2,012 and ~~$898~~$2,617 for the three months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively. Amortization expense related to software technology recorded as cost of revenue was ~~$3,007~~$3,807 and ~~$903~~$3,030 for the three months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively.

Amortization expense related to customer relationships and trade name and contracts ~~recorded as operating expenses in the consolidated statements of comprehensive income~~ was ~~$7,889~~$4,059 and ~~$2,692~~$5,321 for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively. Amortization expense related to software technology ~~recorded as cost of revenue~~ was ~~$9,064~~$7,208 and ~~$2,710~~$6,057 for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively.

The following table summarizes the remaining estimated amortization of definite-lived intangible assets as of ~~December 31, 2016:~~September 30, 2017:


	Amortization Expense Recorded As:						Amortization Expense Recorded As:
	Operating Expense		Cost of Revenue		Total		Operating Expense		Cost of Revenue		Total
For the year ended March 31,
2017 (remaining three months)	2,527		2,963		5,490
2018	7,264		11,851		19,115
2018 (remaining six months)							3,874		8,256		12,130
2019	4,852		11,851		16,703		5,577		16,511		22,088
2020	3,855		11,851		15,706		4,580		16,511		21,091
2021	3,006		7,968		10,974		3,731		12,628		16,359
2022 and beyond	6,012		722		6,734
2022							2,593		4,840		7,433
2023 and beyond							6,056		1,589		7,645
Total	$	27,516	$	47,206	$	74,722	$	26,411	$	60,335	$	86,746

6. Capitalized Software Costs

Our capitalized software costs are summarized as follows:


	December 31, 2016			March 31, 2016			September 30, 2017			March 31, 2017
Gross carrying amount	$	103,070		$	96,699		$	111,180		$	104,948
Accumulated amortization	(90,075		)	(83,449		)	(90,156		)	(91,341		)
Net capitalized software costs	$	12,995		$	13,250		$	21,024		$	13,607

Amortization expense related to capitalized software costs was ~~$1,807~~$1,300 and ~~$2,499~~$2,448 for the three months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively, and is recorded as cost of revenue in the consolidated statements of comprehensive income. ~~Amortization~~

Amortization expense related to capitalized software costs was ~~$6,626~~$2,571 and ~~$7,428~~$4,819 for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively.

The following table presents the remaining estimated amortization of capitalized software costs as of ~~December 31, 2016.~~September 30, 2017. The estimated amortization is comprised of (i) amortization of released products and (ii) the expected amortization for products that are not yet available for sale based on their estimated economic lives and projected general release dates.


For the year ended March 31,
2017 (remaining three months)	$	1,500
2018	5,300
2018 (remaining six months)			$	4,700
2019	4,300		9,100
2020	1,895		4,700
2021			2,524
Total	$	12,995	$	21,024

7. Line of Credit

On January 4, 2016, we entered into a $250,000 revolving credit agreement (“Credit Agreement”) with JP Morgan Chase Bank, N.A., as administrative agent, U.S. Bank National Association, as syndication agent, and certain other lenders. The Credit Agreement is secured by substantially all of our existing and future property and material domestic subsidiaries. The Credit Agreement provides a subfacility of up to $10,000 for letters of credit and a subfacility of up to $10,000 for swing-line loans. The Credit Agreement matures on January 4, 2021 and the full balance of the revolving loans and all other obligations under the agreement must be paid at that time. The revolving loans under the Credit Agreement will be available for letters of credit, working capital and general corporate purposes. We were in compliance with all covenants under the Credit Agreement as of ~~December 31, 2016.~~September 30, 2017.

As of ~~December 31, 2016,~~September 30, 2017, we had ~~$25,000~~$55,000 in outstanding loans and ~~$225,000~~$195,000 of unused credit under the Credit Agreement. As of March 31, 2017, we had $15,000 in outstanding loans under the Credit Agreement.

~~During~~Interest expense related to the Credit Agreement was $520 and $740 for the three months ended ~~December 31,~~September 30, 2017 and 2016, ~~we recorded $359 of interest expense and $269 in amortization~~respectively. Amortization of deferred debt issuance costs was $269 for both the three months ended September 30, 2017 and 2016.

Interest expense related to the Credit ~~Agreement. During~~Agreement was $927 and $1,272 for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016, ~~we recorded $1,631 of interest expense and $807 in amortization~~respectively. Amortization of deferred debt issuance costs ~~related to~~was $538 for both the ~~Credit Agreement.~~six months ended September 30, 2017 and 2016, respectively.

8. Composition of Certain Financial Statement Captions

Accounts receivable may include amounts invoiced for undelivered products and services at each period end. Undelivered products and services are included as a component of the deferred revenue balance on the accompanying consolidated balance sheets.


	December 31, 2016			March 31, 2016			September 30, 2017			March 31, 2017
Accounts receivable, gross	$	86,388		$	104,467		$	90,753		$	93,377
Sales return reserve	(8,623		)	(7,541		)	(6,413		)	(7,213		)
Allowance for doubtful accounts	(2,249		)	(2,902		)	(2,628		)	(2,757		)
Accounts receivable, net	$	75,516		$	94,024		$	81,712		$	83,407

Inventory is comprised of computer systems and components.

Prepaid expenses and other current assets are summarized as follows:


	December 31, 2016		March 31, 2016		September 30, 2017		March 31, 2017
Prepaid expenses	$	13,448	$	11,804	$	13,651	$	14,884
Other current assets	2,496		3,106		1,718		3,085
Prepaid expenses and other current assets	$	15,944	$	14,910	$	15,369	$	17,969

Equipment and improvements are summarized as follows:


	December 31, 2016			March 31, 2016			September 30, 2017			March 31, 2017
Computer equipment	$	21,483		$	32,213		$	26,120		$	22,014
Internal-use software	10,899			10,201			13,290			13,053
Furniture and fixtures	10,561			9,799			12,025			10,472
Leasehold improvements	16,538			13,408			17,258			16,360
Equipment and improvements, gross	59,481			65,621			68,693			61,899
Accumulated depreciation and amortization	(33,384		)	(39,831		)	(41,012		)	(34,473		)
Equipment and improvements, net	$	26,097		$	25,790		$	27,681		$	27,426

The current portion of deferred revenues are summarized as follows:


	December 31, 2016		March 31, 2016		September 30, 2017		March 31, 2017
Professional services	$	22,005	$	23,128	$	22,084	$	21,889
Software license, hardware and other	10,469		14,913		11,579		12,680
Support and maintenance	8,948		11,902		10,203		9,691
Software related subscription services	8,341		7,992		8,419		8,123
Deferred revenue	$	49,763	$	57,935	$	52,285	$	52,383

Accrued compensation and related benefits are summarized as follows:


	December 31, 2016		March 31, 2016		September 30, 2017		March 31, 2017
Payroll, bonus and commission	$	10,617	$	9,683	$	8,869	$	15,836
Vacation	8,003		8,987		8,733		8,677
Accrued compensation and related benefits	$	18,620	$	18,670	$	17,602	$	24,513

Other current and noncurrent liabilities are summarized as follows:

December 31,
2016 March 31,
2016
Contingent consideration and other liabilities related to acquisitions $ 18,367
$ 24,153
Care services liabilities 4,647
5,339
Customer credit balances and deposits 3,973
4,123
Accrued EDI expense 2,270
2,604
Accrued consulting and outside services 2,194
3,650
Accrued self insurance expense 1,898
1,862
Accrued outsourcing costs 1,613
1,604
Deferred rent 1,409
828
Accrued legal expense 758
864
Accrued royalties 740
2,341
Employee benefit plan withholdings 639
213
Sales tax payable 333
655
Other accrued expenses 5,497
2,002
Other current liabilities $ 44,338
$ 50,238

Deferred rent $ 9,538
$ 6,577
Uncertain tax position and related liabilities 4,729
4,084
Other noncurrent liabilities $ 14,267
$ 10,661



	September 30, 2017		March 31, 2017
Care services liabilities	$	6,488	$	4,957
Customer credit balances and deposits	3,964		4,124
Accrued consulting and outside services	3,006		2,496
Accrued self insurance expense	2,502		1,697
Accrued EDI expense	2,469		2,490
Deferred rent and lease obligations	2,275		2,427
Accrued outsourcing costs	1,678		1,588
Accrued legal expense	1,245		853
User group meeting deposits	1,157		—
Accrued hosting costs	951		401
Accrued royalties	721		2,033
Employee benefit plan withholdings	671		739
Sales tax payable	494		448
Contingent consideration and other liabilities related to acquisitions	—		18,817
Other accrued expenses	4,292		3,705
Other current liabilities	$	31,913	$	46,775

Deferred rent and lease obligations	$	11,660	$	11,402
Uncertain tax positions	5,305		4,762
Other liabilities	350		297
Other noncurrent liabilities	$	17,315	$	16,461

9. Income Taxes

The provision for income taxes for the three months ended ~~December 31,~~September 30, 2017 and 2016 was ~~$2,342~~$2,493 and ~~the provision for income taxes~~$1,925, respectively. The effective tax rates were 23.7% and 32.6% for the three months ended ~~December 31, 2015 was $1,141. The effective tax rates were 18.3%~~September 30, 2017 and ~~13.5% for the three months ended December 31,~~ 2016, ~~and 2015,~~ respectively. The effective rate for the three months ended December 31, 2016 increased compared to the prior year period primarily due to the impact of lower qualifying production activity deductions in the current period, certain non-deductible acquisition-related costs, and a discrete valuation allowance, offset by federal and state research and development credit and other discrete adjustments.

The provision for income taxes for the nine months ended December 31, 2016 was $3,950 and the provision for income taxes for the nine months ended December 31, 2015 was $8,233. The effective tax rates were 22.2% and 27.3% for the nine months ended December 31, 2016 and 2015, respectively. The effective rate for the nine months ended December 31, 2016September 30, 2017 decreased compared to the prior year period primarily due to a favorable ~~discrete adjustments for federal~~decline in the amount of certain non-deductible acquisition related costs and ~~state research and development credit, offset by non-deductible acquisition-related costs, lower qualifying production activity deductions in~~ the current period reduction in state taxes.

The provision for income taxes for the six months ended September 30, 2017 and ~~other discrete adjustments.~~2016 was $4,647 and $1,608, respectively. The effective tax rates were 28.0% and 32.5% for the six months ended September 30, 2017 and 2016, respectively. The effective rate for the six months ended September 30, 2017 decreased compared to the prior year period primarily due to a favorable decline in the amount of certain non-deductible acquisition related costs, the current period reduction in state taxes, and the impact of excess tax deficiencies from share-based compensation recorded in the period.

Additionally, we adopted ASU 2016-09 (see Note 1), which requires excess tax expense and benefits to be recorded in the income statement (income tax expense and/or benefit). Prior to adoption of ASU 2016-09, such amounts were recorded to additional paid-in capital and did not impact the effective tax rate.

The deferred tax assets and liabilities have been shown net in the accompanying consolidated balance sheets as noncurrent. We expect to receive the full benefit of the deferred tax assets recorded with the exception of certain state credits, state net operating loss carryforwards, and foreign accumulated minimum tax credits, for which we have recorded a valuation allowance.

Uncertain tax positions

We had liabilities of ~~$4,729~~$5,305 and ~~$4,084~~$4,762 for unrecognized tax benefits related to various federal, state and local income tax matters as of ~~December 31, 2016~~September 30, 2017 and March 31, ~~2016,~~2017, respectively. If recognized, this amount would reduce our effective tax rate.

We are no longer subject to U.S. federal income tax examinations for tax years before ~~2013.~~fiscal years ended 2014. With a few exceptions, we are no longer subject to state or local income tax examinations for tax years before ~~2012.~~fiscal years ended 2013. We do not anticipate that total unrecognized tax benefits will significantly change due to the settlement of audits or the expiration of statute of limitations within the next twelve months.

10. Earnings per Share

The dual presentation of “basic” and “diluted” earnings per share is provided below. Share amounts below are in thousands.


	Three Months Ended December 31,				Nine Months Ended December 31,				Three Months Ended September 30,				Six Months Ended September 30,
	2016		2015		2016		2015		2017		2016		2017		2016
Earnings per share — Basic:
Net income	$	10,486	$	7,302	$	13,826	$	21,979	$	8,030	$	3,987	$	11,926	$	3,340
Weighted-average shares outstanding — Basic	62,093		60,867		61,645		60,548		63,513		61,658		63,077		61,420
Net income per common share — Basic	$	0.17	$	0.12	$	0.22	$	0.36	$	0.13	$	0.06	$	0.19	$	0.05

Earnings per share — Diluted:
Net income	$	10,486	$	7,302	$	13,826	$	21,979	$	8,030	$	3,987	$	11,926	$	3,340
Weighted-average shares outstanding	62,093		60,867		61,645		60,548		63,513		61,658		63,077		61,420
Effect of potentially dilutive securities	—		412		255		642		17		394		12		284
Weighted-average shares outstanding — Diluted	62,093		61,279		61,900		61,190		63,530		62,052		63,089		61,704
Net income per common share — Diluted	$	0.17	$	0.12	$	0.22	$	0.36	$	0.13	$	0.06	$	0.19	$	0.05

The computation of diluted net income per share does not include ~~3,054~~2,567 and ~~3,015~~2,565 options to acquire shares of common stock for the three and ~~nine~~six months ended ~~December 31, 2016,~~September 30, 2017, respectively, because their inclusion would have an anti-dilutive effect on net income per share.

The computation of diluted net income per share does not include ~~1,839~~3,230 and ~~1,789~~2,997 options to acquire shares of common stock for the three and ~~nine~~six months ended ~~December 31, 2015,~~September 30, 2016, respectively, because their inclusion would have an anti-dilutive effect on net income per share.

11. Share-Based Awards

Employee Stock Option and Incentive Plans

In October 2005, our shareholders approved a stock option and incentive plan (the “2005 Plan”) under which 4,800,000 shares of common stock were reserved for the issuance of awards, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock units, performance shares, performance units (including performance options) and other share-based awards. The 2005 Plan provides that our employees and directors may, at the discretion of the Board of Directors ("Board") or a duly designated compensation committee, be granted certain share-based awards. In the case of option awards granted under the 2005 Plan, the exercise price of each option is determined based on the date of grant and expire no later than 10 years from the date of grant. Awards granted pursuant to the 2005 Plan are subject to the vesting schedule or performance metrics set forth in the agreements pursuant to which they are granted. Upon a change of control of our Company, as such term is defined in the 2005 Plan, awards under the 2005 Plan will fully vest under certain circumstances. The 2005 Plan expired on May 25, 2015. As of ~~December 31, 2016,~~September 30, 2017, there were ~~969,565~~702,860 outstanding options ~~and 567 outstanding shares of restricted stock awards~~ under the 2005 Plan.

In August 2015, our shareholders approved a stock option and incentive plan (the “2015 ~~Plan��~~Plan”) under which 11,500,000 shares of common stock were reserved for the issuance of awards, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock awards and restricted stock unit awards, performance stock awards and other share-based awards. In August 2017, our shareholders approved an amendment to our 2015 Equity Incentive Plan, (the “Amended 2015 Plan”), to, among other items, increase the number of shares of common stock reserved for issuance thereunder by 6,000,000. The Amended 2015 Plan provides that our employees and directors may, at the discretion of the Board of Directors or a duly designated compensation committee, be granted certain share-based awards. In the case of option awards granted under the Amended 2015 Plan, the exercise price of each option is determined based on the date of grant and expire no later than 10 years from the date of grant. Awards granted pursuant to the Amended 2015 Plan are subject to the vesting schedule or performance metrics set forth in the agreements pursuant to which they are granted. Upon a change of control of our Company, as such term is defined in the Amended 2015 Plan, awards under the Amended 2015 Plan will fully vest under certain circumstances. As of ~~December 31, 2016,~~September 30, 2017, there were ~~1,994,750~~1,989,375 outstanding options, ~~933,165~~1,619,002 outstanding shares of restricted stock awards, ~~123,082~~114,916 outstanding shares of performance stock awards, and ~~8,079,983~~11,352,428 shares available for future grant under the Amended 2015 Plan.

The following table summarizes the stock option transactions during the ~~nine~~six months ended ~~December 31, 2016:~~September 30, 2017:

Number of
Shares

Weighted-
Average
Exercise
Price
per Share

Weighted-
Average
Remaining
Contractual
Life (years)

Aggregate
Intrinsic
Value
(in thousands)
Outstanding, April 1, 2016 2,447,286
$ 19.55
6.3 $ 574
Granted 1,056,500
12.82
7.4
Forfeited/Canceled (539,471 ) 22.13
4.7

Outstanding, December 31, 2016 2,964,315
$ 16.68
6.4 $ 377
Vested and expected to vest, September 30, 2016 2,652,038
$ 16.93
6.3 $ 329
Exercisable, December 31, 2016 586,120
$ 25.05
3.9 $ 11



	Number of Shares		Weighted- Average Exercise Price per Share		Weighted- Average Remaining Contractual Life (years)	Aggregate Intrinsic Value (in thousands)
Outstanding, April 1, 2017	2,885,415		$	15.41	6.2	$	3,150
Granted	334,000		16.03		7.7
Exercised	(216,405	)	16.62		6.2	$	119
Forfeited/Canceled	(310,775	)	17.75		5.1
Outstanding, September 30, 2017	2,692,235		$	16.44	6.0	$	4,012
Vested and expected to vest, September 30, 2017	2,440,400		$	16.64	5.9	$	2,885
Exercisable, September 30, 2017	921,280		$	20.10	4.6	$	768

We utilize the Black-Scholes valuation model for estimating the fair value of share-based compensation with the following assumptions:


					Three Months Ended September 30,		Six Months Ended September 30,
	Three Months Ended December 31,		Nine Months Ended December 31,		2017	2016	2017	2016
	2016	2015	2016	2015
Expected term	6.3 years	3.9 years	6.0 - 6.6 years	3.8 - 3.9 years	5.6 years	6.6 years	5.6 - 5.7 years	6.0 - 6.6 years
Expected volatility	37.1%	38.9%	36.9% - 37.4%	38.3% - 38.9%	37.2%	36.9%	37.2% - 37.7%	36.9% - 37.4%
Expected dividends	—%	5.3%	—%	4.1% - 5.3%	—%	—%	—%	—%
Risk-free rate	1.5%	1.3%	1.2% - 1.5%	1.3% - 1.6%	1.9%	1.2%	1.9%	1.2% - 1.5%

The weighted-average grant date fair value of stock options granted during the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 was $6.11 and ~~2015 was~~ $4.92 ~~and $3.33~~ per share, respectively.

During the ~~nine~~six months ended ~~December 31, 2016,~~September 30, 2017, a total of ~~1,056,500~~334,000 options to purchase shares of common stock were granted under the Amended 2015 Plan at an exercise price equal to the market price of our common stock on the date of grant, as summarized below:

Option Grant Date Number of Shares Exercise Price
Vesting Terms ⁽¹⁾
Expiration
November 1, 2016 50,000
$ 12.71
Four years November 1, 2024
July 11, 2016 150,000
$ 12.60
Four years July 11, 2024
May 31, 2016 100,000
$ 12.71
Five years May 31, 2024
May 25, 2016 216,500
$ 12.78
Four years May 25, 2024
May 24, 2016 540,000
$ 12.93
Four years May 24, 2024
Fiscal year 2017 grants 1,056,500



Option Grant Date	Number of Shares	Exercise Price		Vesting Terms ⁽¹⁾	Expiration

June 13, 2017	249,000	$	16.37	Four years	June 13, 2025
May 24, 2017	60,000	$	14.57	Four years	May 24, 2025
August 4, 2017	25,000	$	16.13	Four years	August 4, 2025

⁽¹⁾ Options vest in equal annual installments on each grant anniversary date commencing one year following the date of grant.

Non-vested stock option award activity during the ~~nine~~six months ended ~~December 31, 2016~~September 30, 2017 is summarized as follows:


	Non-Vested Number of Shares		Weighted- Average Grant-Date Fair Value per Share		Non-Vested Number of Shares		Weighted- Average Grant-Date Fair Value per Share
Outstanding, April 1, 2016	1,859,750		$	4.67
Outstanding, April 1, 2017					2,073,295		$	5.09
Granted	1,056,500		4.92		334,000		6.11
Vested	(276,595	)	4.30		(430,190	)	4.86
Forfeited/Canceled	(261,460	)	4.38		(206,150	)	4.57
Outstanding, December 31, 2016	2,378,195		$	4.72
Outstanding, September 30, 2017					1,770,955		$	4.98

As of ~~December 31, 2016, $8,662~~September 30, 2017, $7,590 of total unrecognized compensation costs related to stock options is expected to be recognized over a weighted-average period of ~~3.2~~3.1 years. This amount does not include the cost of new options that may be granted in future periods or any changes in our forfeiture percentage. The total fair value of options vested during the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 was $2,092 and ~~2015 was $1,189 and $1,564,~~$1,486, respectively.

Restricted stock awards activity during the ~~nine~~six months ended ~~December 31, 2016~~September 30, 2017 is summarized as follows:


	Number of Shares		Weighted- Average Grant-Date Fair Value per Share		Number of Shares		Weighted- Average Grant-Date Fair Value per Share
Outstanding, April 1, 2016	191,247		$	14.44
Outstanding, April 1, 2017					902,948		$	12.92
Granted	857,456		12.81		1,081,374		15.57
Vested	(68,309	)	14.29		(288,304	)	12.57
Canceled	(46,662	)	12.78		(77,016	)	13.81
Outstanding, December 31, 2016	933,732		$	12.80
Outstanding, September 30, 2017					1,619,002		$	14.79

Share-based compensation expense related to restricted stock awards was ~~$1,054~~$2,207 and ~~$249~~$972 for the three months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively. Share-based compensation expense related to restricted stock awards was ~~$2,571~~$3,746 and ~~$664~~$1,517 for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively.

The weighted-average grant date fair value for the restricted stock awards was estimated using the market price of the common stock on the date of grant. The fair value of the restricted stock awards is amortized on a straight-line basis over the vesting period, which is generally ~~two~~between one to three years.

As of ~~December 31, 2016, $9,930~~September 30, 2017, $20,842 of total unrecognized compensation costs related to restricted stock awards is expected to be recognized over a weighted-average period of ~~2.2~~2.4 years. This amount does not include the cost of new restricted stock awards that may be granted in future periods.

On December 29, 2016, the Compensation Committee of the Board granted 123,082 performance stock awards to certain executive ~~officers.~~officers, of which 114,916 shares are currently outstanding. The performance stock awards vest in four equal increments on each of the first four anniversaries of the grant date, subject in each case to the executive officer’s continued service and achievement of certain Company performance goals, including strong Company stock price performance. Share-based compensation expense related to the performance stock awards was ~~not significant~~$77 and $150 for the three and ~~nine~~six months ended ~~December 31, 2016.~~

September 30, 2017, respectively.

Employee Share Purchase Plan

On August 11, 2014, our shareholders approved an Employee Share Purchase Plan (the “Purchase Plan”) under which 4,000,000 shares of common stock were reserved for future grant. The Purchase Plan allows eligible employees to purchase shares through payroll deductions of up to 15% of total base salary at a price equal to 90% of the lower of the fair market values of the shares as of the beginning or the end of the corresponding offering period. Any shares purchased under the Purchase Plan are subject to a six-month holding period. Employees are limited to purchasing no more than 1,500 shares on any single purchase date and no more than $25,000 in total fair market value of shares during any one calendar year. As of ~~December 31, 2016,~~September 30, 2017, we have issued ~~209,876~~290,649 shares under the Purchase Plan and ~~3,790,124~~3,709,351 shares are available for future issuance.

Share-based compensation expense recorded for the employee share purchase plan was ~~$70~~$80 and ~~$70~~$81 for the three months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively. Share-based compensation expense recorded for the employee share purchase plan was ~~$277~~$177 and ~~$216~~$207 for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively.

12. Concentration of Credit Risk

We had cash deposits at U.S. banks and financial institutions which exceeded federally insured limits at ~~December 31, 2016.~~September 30, 2017. We are exposed to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, we do not anticipate non-performance by these institutions.

13. Commitments, Guarantees and Contingencies

Commitments and Guarantees

Our software license agreements include a performance guarantee that our software products will substantially operate as described in the applicable program documentation for a period of 365 days after delivery. To date, we have not incurred any significant costs associated with our performance guarantee or other related warranties and do not expect to incur significant

warranty costs in the future. Therefore, no accrual has been made for potential costs associated with these warranties. Certain arrangements also include performance guarantees related to response time, availability for operational use, and other performance-related guarantees. Certain arrangements also include penalties in the form of maintenance credits should the performance of the software fail to meet the performance guarantees. To date, we have not incurred any significant costs associated with these warranties and do not expect to incur significant warranty costs in the future. Therefore, no accrual has been made for potential costs associated with these warranties.

We have historically offered short-term rights of return in certain sales arrangements. If we are able to estimate returns for these types of arrangements and all other criteria for revenue recognition have been met, revenue is recognized and these arrangements are recorded in the consolidated financial statements. If we are unable to estimate returns for these types of arrangements, revenue is not recognized in the consolidated financial statements until the rights of return expire, provided also, that all other criteria of revenue recognition have been met.

Our standard sales agreements contain an indemnification provision pursuant to which we shall indemnify, hold harmless, and reimburse the indemnified party for losses suffered or incurred by the indemnified party in connection with any United States patent, any copyright or other intellectual property infringement claim by any third-party with respect to our software. As we have not incurred any significant costs to defend lawsuits or settle claims related to these indemnification agreements, we believe that our estimated exposure on these agreements is currently minimal. Accordingly, we have no liabilities recorded for these indemnification obligations.

Hussein Litigation

On October 7, 2013, a complaint was filed against our Company and certain of our officers and directors in the Superior Court of the State of California for the County of Orange, captioned Ahmed D. Hussein v. Sheldon Razin, Steven Plochocki, Quality Systems, Inc. and Does 1-10, inclusive, No. 30-2013-00679600-CU-NP-CJC, by Ahmed Hussein, a former director and significant shareholder of our Company. We filed a demurrer to the complaint, which the Court granted on April 10, 2014. An amended complaint was filed on April 25, 2014. The amended complaint generally alleges fraud and deceit, constructive fraud, negligent misrepresentation and breach of fiduciary duty in connection with statements made to our shareholders regarding our financial condition and projected future performance. The amended complaint seeks actual damages, exemplary and punitive damages and costs. We filed a demurrer to the amended complaint. On July 29, 2014, the Court sustained the demurrer with respect to the breach of fiduciary duty claim, and overruled the demurrer with respect to the fraud and deceit claims. On August 28, 2014, we filed an answer and also filed a cross-complaint against ~~the plaintiff,~~Hussein, alleging that ~~the plaintiff~~he breached fiduciary duties owed to the Company, Mr. Razin and Mr. Plochocki. Mr. Razin and Mr. Plochocki have dismissed their claims against Hussein, leaving QSI as the sole plaintiff in the cross-complaint. On June 26, 2015, we filed a motion for summary judgment with respect to Hussein’s claims, which the Court granted on September 16, 2015, dismissing all of Hussein’s claims against us. On September 23, 2015, ~~the plaintiff~~Hussein filed an application for reconsideration of the Court's summary judgment order, which the Court denied. Hussein filed a renewed application for reconsideration of the Court’s summary judgment order on August 3, 2017. Argument on the renewed application for reconsideration is scheduled for October 26, 2017.

dismiss our cross-complaint. The Court denied each motion. Trial on our cross-complaint ~~which~~began June 12, 2017. On July 26, 2017, the Court ~~denied~~issued a statement of decision granting Hussein’s motion for judgment on ~~September 2, 2016. Trial is set for April 10, 2017~~our cross-complaint. We believe the Court’s decision on ~~QSI's cross-complaint.~~our cross-complaint was erroneous and we are evaluating a potential appeal. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

Federal Securities Class Action

On November 19, 2013, a putative class action complaint was filed on behalf of the shareholders of our Company other than the defendants against us and certain of our officers and directors in the United States District Court for the Central District of California by one of our shareholders. After the Court appointed lead plaintiffs and lead counsel for this action, and recaptioned the action In re Quality Systems, Inc. Securities Litigation, No. ~~8L13-cv-01818-CJC(JPRx),~~8:13-cv-01818-CJC-JPR, lead plaintiffs filed an amended complaint on April 7, 2014. The amended complaint, which is substantially similar to the litigation described above under the caption “Hussein Litigation,” generally alleges that statements made to our shareholders regarding our financial condition and projected future performance were false and misleading in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the individual defendants are liable for such statements because they are controlling persons under Section 20(a) of the Exchange Act. The complaint seeks compensatory damages, court costs and attorneys' fees. We filed a motion to dismiss the amended complaint on June 20, 2014, which the Court granted on October 20, 2014, dismissing the complaint with prejudice. Plaintiffs filed a motion for reconsideration of the Court's order, which the Court denied on January 5, 2015. On January 30, 2015, Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Ninth Circuit, captioned In re Quality Systems, Inc. Securities Litigation, No. 15-55173. ~~Plaintiffs filed their opening brief and we answered.~~ Oral argument was held on December 5, 2016. ~~The~~On July 28, 2017, the Ninth Circuit issued a decision reversing and remanding the District Court's ~~decision remains pending.~~order on our motion to dismiss. On September 5, 2017, we filed a petition for rehearing en banc, which was denied on September 29, 2017. We believe that the plaintiffs' claims are without merit and continue to defend against them ~~vigorously.~~vigorously, including by evaluating potential challenges to the Ninth Circuit decision. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

Shareholder Derivative Litigation

On January 24, 2014, a complaint was filed against our Company and certain of our officers and current and former directors in the United States District Court for the Central District of California, captioned Timothy J. Foss, derivatively on behalf of himself and all others similarly situated, vs. Craig A. Barbarosh, George H. Bristol, James C. Malone, Peter M. Neupert, Morris Panner, D. Russell Pflueger, Steven T. Plochocki, Sheldon Razin, Lance E. Rosenzweig and Quality Systems, Inc., No. SACV14-00110-DOC-JPPx, by Timothy J. Foss, a purported shareholder of ours. The complaint arises from the same allegations described above under the captions “Hussein Litigation” and “Federal Securities Class Action” and generally alleges breach of fiduciary duties, abuse of control and gross mismanagement by our directors, in addition to unjust enrichment and insider selling by individual directors. The complaint seeks compensatory damages, restitution and disgorgement of all profits, court costs, attorneys’ fees and implementation of enhanced corporate governance procedures. The parties have agreed to stay this litigation until the United States Court of Appeals for the Ninth Circuit issues a ruling on the pending appeal described above under the caption “Federal Securities Class ~~Action”.~~ Action,” and will meet and confer to discuss process going forward.

On September 28, 2017, a complaint was filed against our Company and certain of our current and former officers and directors in the United States District Court for the Central District of California, captioned Kusumam Koshy, derivatively on behalf of Quality Systems Inc. vs. Craig Barbarosh, George H. Bristol, James C. Malone, Peter M. Neupert, Morris Panner, D. Russell Pflueger, Steven T. Plochocki, Sheldon Razin, Lance E. Rosenzweig, Paul A. Holt, and Quality Systems, Inc., No. 8:17-cv-01694, by Kusumam Koshy, a purported shareholder of ours. The complaint alleges breach of fiduciary duties and abuse of control, as well as unjust enrichment and insider selling by individual directors arising out of the allegations described above under the captions “Hussein Litigation” and “Federal Securities Class Action,” QSI’s adoption of revised indemnification agreements, and the resignation of certain officers of the Company. The complaint seeks restitution and disgorgement, court costs and attorneys’ fees, and enhanced corporate governance reforms and internal control procedures.

We believe that the ~~plaintiff’s~~plaintiffs’ claims are without merit and intend to defend against them vigorously. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

Other Regulatory Matters

~~14. Operating Segment Information~~

~~Effective July 1, 2016,~~In April 2017, we ~~revised~~received a request for documents and information from the U.S. Attorney's Office for the District of Vermont pursuant to a Civil Investigative Demand (“CID”). The CID relates to an investigation concerning the certification we obtained for our ~~reportable operating segments. As part~~software under the U.S. Department of Health and Human Services' Electronic Health Record Incentive Program. Given the highly-regulated nature of our ~~ongoing reorganization efforts,~~industry, we ~~refined the measurement of~~may, from time to time, be subject to subpoenas, requests for information, or investigations from various government agencies. It is our ~~segment data~~practice to better reflect our current internal organizational structure whereby certain functions that formerly existed within each individual operating segment have changed. Our operating segments now consist of the Softwarerespond to such matters in a cooperative, thorough and ~~Related Solutions segment~~timely manner. We are currently responding to this CID and ~~the RCM and Related Services segment, which is consistent~~intend to cooperate fully with the ~~disaggregated financial information used~~government. Requests and ~~evaluated by our chief operating decision maker (consisting~~investigations of our Chief Executive Officer) to assess performance and make decisions about the allocation of resources. Revenue and gross profit are the key measures of segment profitability used by our chief operating decision maker to measure segment operating performance and to make key business decisions. The revenues and gross profit of each segment are derived from distinct product and services within each segment. The Software and Related Solutions segment aggregates the revenues and gross profit of our software-related products and services, including software license and hardware, software-related subscription services, support and maintenance, EDI and data services, and certain professional services, such as implementation, training, and consulting. The RCM and Related Services segment aggregates the revenues and gross profit of our RCM services and certain related ancillary service offerings.

Certain functional roles that do not engage in revenue generating activities, such as product solutions and strategy, research and development, and certain corporate general and administrative functions, including finance, human resources, marketing, and legal, are considered to be shared-services and are not controlled by segment-level leadership. Although the segmentsthis nature may derive direct benefits as a result of such shared-services functions, our chief operating decision maker evaluates performance based upon stand-alone segment revenues and gross profit. Accordingly, the shared-services functions are not considered separate operating segments, and the related operating expenses are not included within our operating segments disclosure. Additionally, total assets are managed at a consolidated level and thus are also not included within our operating segments disclosure. Accounting policies for each of our operating segments are the same as those applied to our consolidated financial statements.

~~Operating segment data for the three and nine months ended December 31, 2016 and~~ ~~2015~~ is summarized in the table below. Prior period data has been retroactively reclassified to present all segment information on a comparable basis. The change in reportable segments has no impact to consolidated revenues and consolidated cost of revenue, nor does it affect our presentation of revenue and cost of revenue on the consolidated statements of comprehensive income.

Three Months Ended December 31, Nine Months Ended December 31,
2016 2015 2016 2015
Revenue:
Software and Related Solutions $ 106,958
$ 93,927
$ 312,854
$ 291,783
RCM and Related Services 20,910
22,486
64,385
65,313
Hospital Solutions⁽¹⁾
—
619
—
7,469
Consolidated revenue $ 127,868
$ 117,032
$ 377,239
$ 364,565

Gross profit (loss):
Software and Related Solutions $ 71,252
$ 58,949
$ 204,414
$ 184,982
RCM and Related Services 7,077
7,769
21,337
20,792
Hospital Solutions⁽¹⁾
—
(69 ) —
2,569
Unallocated cost of revenue⁽²⁾
(4,813 ) (3,402 ) (15,676 ) (10,138 )
Consolidated gross profit $ 73,516
$ 63,247
$ 210,075
$ 198,205

⁽¹⁾ ~~The former Hospital Solutions Division was divested in October 2015 and therefore, does not represent a distinct operating segment. Historical amounts for Hospital Solutions have not been revised.~~

⁽²⁾ ~~Consists of amortization of acquired software technology and amortization of capitalized software costs not allocated~~lead to the ~~operating segments for~~assertion of claims or the ~~purposes~~commencement of ~~measuring performance.~~legal proceedings against us, as well as other material liabilities. In addition, our responses to the CID require time and effort, which can result in additional cost to us. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

~~15.~~14. Restructuring Plan

In fiscal year 2016, we initiated a three-phase plan intended to better position our organization for future success. We implemented a series of actions with the objective of achieving greater synergies and further integration of our products and services in support of our business strategies, and enabling a more efficient, integrated and client-centered delivery of the holistic solutions that we believe is required by our ambulatory care clients. We also transformed our management team with the appointment of a new chief executive officer, chief financial officer, chief technology officer, chief strategy officer, and chief client officer. In the first phase, we redesigned the organization to more effectively support the execution of our strategy. Under phase twoas part of our reorganization we will continue to build our infrastructure and enhance our healthcare information technology capabilities to drive future revenue growth. The third phase of the plan will consist of developing and marketing the services and solutions that we believe will accelerate revenue growth.

The overall plan also includes a multi-year initiative, called NextGen 2.0, to merge our business units into a more streamlined, functional-based organization structure and to realign our organizational structure by consolidating the sales, marketing, information services, and software development responsibilities into single, company-wide roles in order to achieve greater efficiency. As a result, our reportable segments have changed and may change again due to such changes in the organization of our business.

~~The first phase was completed in April 2016, when we announced a corporate restructuring plan, which was approved by our Board of Directors. During the three and nine months ended December 31, 2016,~~efforts, we recorded ~~$231 and $4,685, respectively,~~$7,078 of restructuring costs within operating expenses in our consolidated statements of net income and comprehensive income. The restructuring plan was substantially complete by the end of fiscal 2017. The restructuring costs ~~consist~~consisted primarily of payroll-related costs, such as severance, outplacement costs, and continuing healthcare coverage, associated with the involuntary separation of employees pursuant to a one-time benefit arrangement, which were accrued when it was probable that the benefits ~~will~~would be paid and the ~~amount~~amounts were reasonably estimable. ~~The~~Also included in restructuring costs were certain facilities-related costs associated with accruals for the remaining ~~restructuring liability~~lease obligations at certain locations, including Solana Beach, Costa Mesa, and a portion of Horsham with contractual lease terms ending between January 2018 and September 2023. We have vacated each of the locations or portions thereof and are actively marketing the locations for sublease. We estimated the remaining lease obligations at fair value as of ~~December 31, 2016~~the cease-use date for each location based on the future contractual lease obligations, reduced by projected sublease rentals that could be reasonably obtained for the locations after a period of marketing, and adjusted for the effect deferred rents that have been recognized under the lease. The effect of discounting future cash flows using a credit-adjusted risk free rate was not significant. ~~The restructuring plan is expected~~Sublease income and commencement dates were estimated based on data available from rental activity in the local markets. Significant judgment was required to ~~be complete by~~estimate the ~~end~~remaining lease obligations at fair value and actual results could vary from the estimates, resulting in potential future adjustments to amounts previously recorded. As of ~~fiscal 2017.~~September 30, 2017, the remaining lease obligation, net of estimated projected sublease rentals, was $1,579.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q ("Report") and certain information incorporated herein by reference contain forward-looking statements within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Report, other than statements that are purely historical, are forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “should,” “would,” “could,” “may,” and similar expressions also identify forward-looking statements. These forward-looking statements include, without limitation, discussions of our product development plans, business strategies, future operations, financial condition and prospects, developments in and the impacts of government regulation and legislation, including, without limitation, The American Recovery and Reinvestment Act, the Patient Protection and Affordable Care Act, and the Medicare Access and CHIP Reauthorization Act of 2015, and market factors influencing our results. Our expectations, beliefs, objectives, intentions and strategies regarding our future results are not guarantees of future performance and are subject to risks and uncertainties, both foreseen and unforeseen, that could cause actual results to differ materially from results contemplated in our forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to continue to develop new products and increase systems sales in markets characterized by rapid technological evolution, consolidation, and competition from larger, better-capitalized competitors. Many other economic, competitive, governmental and technological factors could affect our ability to achieve our goals, and interested persons are urged to review any risks that may be described in “Item 1A. Risk Factors” as set forth herein and other risk factors appearing in our most recent Annual Report on Form 10-K for the fiscal year ended March 31, ~~2016~~2017 (“Annual Report”), as supplemented by additional risk factors, if any, in our interim filings on our Quarterly Reports on Form 10-Q, as well as in our other public disclosures and filings with the Securities and Exchange Commission ("SEC"). Because of these risk factors, as well as other variables affecting our financial condition and results of operations, past financial performance may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods. We assume no obligation to update any forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of the filing of this Report.

This management's discussion and analysis of financial condition and results of operations ("MD&A") is provided as a supplement to the consolidated financial statements and notes thereto included elsewhere in this Report in order to enhance your understanding of our results of operations and financial condition and should be read in conjunction with, and is qualified in its entirety by, the consolidated financial statements and related notes thereto included elsewhere in this Report. Historical results of operations, percentage margin fluctuations and any trends that may be inferred from the discussion below are not necessarily indicative of the operating results for any future period.

Company Overview

Quality Systems, Inc., ~~primarily through its~~known to our clients as NextGen Healthcare, ~~subsidiary,~~ provides ~~technology-based~~software, services and analytics solutions ~~and services~~ to the ambulatory care ~~market in~~market. We are a healthcare information technology and services company that delivers the ~~United States. Our solutions provide our clients with the ability~~foundational capabilities to ~~redesign patient care and other workflow processes while improving productivity through the facilitation of managed access~~organizations that want to ~~patient information. We help~~ promote healthy ~~communities by empowering~~communities. Our technology provides a customizable platform that empowers physician practice success, ~~and enriching~~enriches the patient care experience ~~while lowering~~and lowers the cost of healthcare.

We primarily derive revenue by developing and marketing software and services that automate certain aspects of practice management (“PM”) and electronic health records (“EHR”) for ~~medical~~ambulatory care practices. In addition, our software and ~~dental practices.~~services facilitate interoperability. Our software can be licensed ~~on a perpetual,~~and delivered on-premise ~~basis, hosted in a private cloud~~ or in ~~certain instances,~~the cloud as a software-as-a-service (“SaaS”) ~~solution.~~. Our services include maintenance and support, professional services, and complementary services such as managed cloud services, revenue cycle management (“RCM”) and electronic data interchange (“EDI”). We market and sell our solutions through a dedicated sales force and to a much lesser extent, through resellers. Our clients ~~include~~span the entire ambulatory market from large multi-specialty to small single specialty practices and ~~small practice physicians,~~include networks of practices such as physician hospital organizations (“PHOs”), management service organizations (“MSOs”), accountable care organizations (“ACOs”), ambulatory care centers and community health centers and medical and dental schools. We also provide implementation, training, support and maintenance for software and complementary services such as revenue cycle management (“RCM”) and electronic data interchange (“EDI”).

We have a history of developing new and enhanced technologies. Over the course of a number of years, we have also made strategic acquisitions to complement and enhance our product portfolio in the ambulatory care, RCM, and hospital markets.centers.

Quality Systems, Inc. was incorporated in California in 1974. Our principal offices are located at 18111 Von Karman Ave., Suite 800, Irvine, California, 92612. Our websites are located at www.nextgen.com and www.qsii.com. We operate on a fiscal year ending on March 31.

Trends and Events in Our Business

We believe that the following trends and events as described below have contributed to our consolidated results of operations and may continue to impact our future results.

We believe healthcare is more heavily influenced by regulatory and national health projects than by the cycles of our economy. The healthcare industry has been significantly impacted by the Obama Administration's broad healthcare reform efforts, including the Health Information Technology for Economic and Clinical Health portion of the American Recovery and Reinvestment Act of 2009 ("

("HITECH Act") and the Patient Protection and Affordable Care Act ("ACA") that provided significant incentives to health care organizations for "Meaningful Use" adoption and interoperable electronic health record solutions.

We also believe that healthcare reform, including the repeal of the sustainable growth rate ~~("SGR")~~(SGR) formula as part of the Medicare Access and CHIP Reauthorization Act of 2015 ("MACRA"), and a movement towards a value-based, pay-for-performance model and quality initiative efforts will stimulate demand for robust electronic health record solutions as well as new health information technology solutions from bundled billing capabilities to patient engagement and population health management. We believe MACRA may be the most important of the three regulations for our market because it permanently changes how ambulatory healthcare providers are reimbursed by Medicare. It offers certainty and a timeline for the market’s move away from volume-based, fee-for-service models to value-based payment models that reward the delivery of lower cost, high quality care.

While we expect to benefit from the increasing demands for greater efficiency as well as government support for increased adoption of electronic health records, the market for physician based electronic health records software is becoming increasingly saturated while physician group practices are rapidly being consolidated by hospitals, insurance payers and other entities. Hospital software providers are leveraging their position with their hospital clients to gain market share with hospital owned physician practices. Insurance providers and large physician groups are also consolidating physician offices creating additional opportunity for ambulatory software providers like us. Our strategy is to focus on addressing the growing needs of accountable care organizations around interoperability, patient engagements, population health, and data analytics.

We believe that our core strength lies in the central role our software products and services play in the delivery of healthcare by the primary physician in an ambulatory setting. We intend to remain at the forefront of upcoming new regulatory requirements and meaningful use requirements for stimulus payments. We intend to continue the development and enhancement of our software solutions to support healthcare reform, such as the recently enacted MACRA, which promotes the transition from fee-for-service to value-based, pay-for-performance and patient-centric and quality initiatives such as accountable care organizations. Key elements of our future software development will be to expand our interoperability capabilities enhancing the competitiveness of our software offerings, make our products more intuitive and easy to use, and to enhance the capability of our MediTouch® Platform to allow us to deliver our software over the cloud to larger ambulatory care practices.

We have a history of enhancing our solutions through both organic and inorganic activities. Over the last few years, we have entered into strategic transactions to complement and enhance our product portfolio in the ambulatory care market. In addition to the activities described above, mergers and acquisitions have been important to our development. In September 2013 we acquired Mirth Corporation ("Mirth"), a global leader in health information technology that helps clients achieve interoperability. In AprilOctober 2015, we ~~acquired Gennius, Inc. ("Gennius"), a population health analytics company which we believe enhances and leverages~~divested our ~~acquisition of Mirth by broadening our business intelligence capabilities in the growing population health and value based care areas.~~former Hospital Solutions division. In January 2016, we ~~completed the acquisition of~~acquired HealthFusion Holdings, Inc. ("HealthFusion"), a cloud-based healthcare information technology (“HCIT”) company providing electronic health record (“EHR”) and practice management (“PM”) software primarily to the one-to-ten physician size market. We entered into a revolving credit agreement to fund the transaction. We believe the acquisition provided us with access to a market we were not in and provides us with technology that will accelerate our transition to the cloud.

We continue to evaluate the organizational structure of our company with the objective of achieving greater synergies and further integration of our products and services, in support of our business strategies. In fiscal 2016, we initiated a three-phase plan to better position our organization for future success. In the first phase, we redesigned the organization to more effectively support the execution of our strategy. We also transformed our management team with the appointment of a new chief executive officer, chief financial officer, chief technology officer, chief strategy officer, and chief client officer. This first phase was completed in April ~~2016, when~~2017, we ~~announced a corporate restructuring plan intended to enable a more efficient, integrated~~acquired Entrada, Inc. ("Entrada"), and ~~client-centered delivery of the holistic solutions that~~in August 2017, we believe is required by our ambulatory care clients. The restructuring plan includes merging our business units into a more streamlined, functional-based organization structure. We are now beginning phase two of our reorganization, which includes building and enhancing the capabilities that will drive future revenue growth. The third phase of the plan will consist of developing and marketing the services and solutions that we believe will accelerate revenue growth.acquired EagleDream Health, Inc. ("EagleDream").

We have ~~made~~ and intend to continue ~~making substantial~~ investments in our infrastructure, ~~while continuing our strong commitment of service in support of our client satisfaction programs and maintaining reasonable expense discipline. Such investments include~~including but ~~are~~ not limited to maintaining and expanding sales, marketing and product development activities to improve patient care and reduce healthcare costs, providing industry-leading, integrated clinical and administrative healthcare data systems, services, and expertise to clinical, medical, technology, and healthcare business ~~professionals.~~professionals while continuing our strong commitment of service in support of our client satisfaction programs. These investments in our infrastructure will continue while maintaining reasonable expense discipline. We ~~also~~ strive to add new clients and expand our relationship with existing clients through delivery of add-on and complementary products and ~~services. We~~services and believe that ~~the~~our client base that ~~uses~~is using our software on a daily basis is a strategic ~~asset, and we~~asset. We intend to leverage this strategic asset by expanding our product and service offerings towards this client base.

Led by our vision and mission, we are resetting our strategy and structure to deliver value to our clients. To achieve a lower-cost, increased ~~structural~~ capability structure, our new management team is building what we believe is an aligned, client-focused organization, supported by a recurring revenue stream and a large and diverse existing client base.

Our Strategy

We strive to be the trusted partner for clients of all ~~size,~~sizes, integrating services ~~software~~ and ~~analytics~~software into a consolidated ~~solution.~~solution that enables an efficient and effective caregiver and patient experience while driving positive financial outcomes. As a healthcare information technology and services company, we plan to continue investing in our current capabilities as well as building and/or acquiring new capabilities as we guide our clients through an evolving healthcare marketplace that is transitioning from fee-for-service to fee-for-value ~~payer~~ reimbursement models. With approximately 90,000 providers using our solutions, we are enabling care and believe we can truly transform the delivery of care through the following strategic priorities:

Focus on the ambulatory client segment. In October 2015, we sold our former Hospital Solutions ~~Division~~division to focus on our core ambulatory clients. Further, a recent operational reorganization better allows us to serve the needs of our ambulatory clients through a simpler, more nimble, and focused organization. We believe it is essential to protect, build and sell new capabilities within our ambulatory ~~platform.~~client segment. We are focused on our core by increasing quality and the serviceability of our solutions. We intend to continue to enhance the capabilities of our NextGen Ambulatory flagship product.

~~Cloud transition.~~ ~~Through our acquisition~~ At the same time, we intend to expand the capability of ~~HealthFusion in January 2016, we acquired a~~the highly scalable, pure cloud-based and mobile-enabled MediTouch® platform.

Platform as a service. With the introduction of our API 2.0 framework and our continued leverage of the Mirth interoperability platform, we will continue our evolution to plug and play extensibility and information sharing that ~~operates under~~allows our customers to innovate and deploy high-fidelity extensions to our core applications without the ~~tradename MediTouch®.~~costs, risks (security, performance, etc.) or complexity commonly associated with direct binding. We ~~intend~~have also introduced platform-enabled automation capabilities to expand the capability of this platform to serve the requirements of larger ambulatory practices. When combined with our Mirth-branded products, we can offer our clients a full suite of cloud-based solutions that better enableempower our clients to ~~focus on care delivery.~~

~~Solutions selling.~~drive cost out of their processes while supporting their needs to implement the highly personalized workflows that are required to support value based care. Our acquisition of Entrada and its cloud-based, mobile application in April 2017 demonstrates our commitment to innovation that becomes essential for practitioners by improving their clinical productivity with documentation support services that seamlessly integrate into their electronic health record. We believe there is significant opportunity to extend the solutions we offer existing and new clients through ~~value added~~value-added services such as RCM ~~EDI, interoperability solutions~~ and ~~professional services. This will evolve our relationships from being a seller of products and services to delivering a consistent solution suite and experience for our clients.~~EDI.

Population health software and services. We are migrating into applications, analytics and services that ~~we believe~~ will enable our clients to ~~be successful in managing~~proactively manage the health of patient populations. We are establishing strong development ~~partners within~~partnerships with our ~~core client base,~~most innovative customers who are actively participating in shared-risk contracts, and working together with them to ~~determine~~create progressive population health ~~solutions.~~

~~More effective use of capital.~~ ~~From cessation of the dividend, leveraging our balance sheet for future opportunities,~~capabilities. We support extraordinary information sharing capabilities vital to managing patient populations through our ~~cost structure, we are transforming our capital strategy. Our recent reorganization was formulated to result in a more efficient, integrated and streamlined organization.~~interoperability offerings.

Critical Accounting Policies and Estimates

The discussion and analysis of our consolidated financial statements and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect our reported amounts of assets, liabilities, revenue and expenses, and related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends, and other factors we believe to be reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. On a regular basis, we review the accounting policies and update our assumptions, estimates, and judgments, as needed, to ensure that our consolidated financial statements are presented fairly and in accordance with GAAP. Actual results could differ materially from our estimates under different assumptions or conditions. To the extent that there are material differences between our estimates and actual results, our financial condition or results of operations will be affected.

We describe our significant accounting policies in Note 2, “Summary of Significant Accounting Policies,” of our notes to consolidated financial statements included in our Annual Report. We discuss our critical accounting policies and estimates in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report. There have been no material changes in our significant accounting policies or critical accounting policies and estimates since the fiscal year ended March 31, ~~2016.~~2017.

Results of Operations

The following table sets forth the percentage of revenue represented by each item in our consolidated statements of comprehensive income for the three and ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and 2015~~ (certain percentages below may not sum due to rounding):


	Three Months Ended December 31,				Nine Months Ended December 31,				Three Months Ended September 30,				Six Months Ended September 30,
	2016		2015		2016		2015		2017		2016		2017		2016
Revenues:
Software license and hardware	13.3	%	13.8	%	13.0	%	14.3	%	10.8	%	13.5	%	10.3	%	12.8	%
Software related subscription services	17.6		10.0		16.9		10.0		18.8		16.9		18.6		16.6
Total software, hardware and related	30.9		23.8		29.9		24.3		29.6		30.4		28.8		29.4
Support and maintenance	31.2		33.8		31.0		34.4		31.4		30.6		31.4		30.9
Revenue cycle management and related services	15.7		18.5		16.4		17.2		15.8		16.5		16.1		16.8
Electronic data interchange and data services	17.0		17.6		17.4		16.8		17.3		17.0		17.6		17.5
Professional services	5.1		6.3		5.3		7.3		5.8		5.5		6.1		5.3
Total revenues	100.0		100.0		100.0		100.0		100.0		100.0		100.0		100.0
Cost of revenue:
Software license and hardware	4.4		5.6		5.1		5.5		3.7		5.1		3.9		5.4
Software related subscription services	7.3		4.7		7.2		4.8		8.1		6.8		8.0		7.1
Total software, hardware and related	11.8		10.3		12.3		10.3		11.7		11.9		11.9		12.6
Support and maintenance	5.7		6.4		5.5		6.5		5.6		5.5		5.7		5.5
Revenue cycle management and related services	10.5		12.3		11.1		12.0		11.2		11.3		11.5		11.5
Electronic data interchange and data services	9.9		10.6		10.1		10.2		10.2		10.1		10.1		10.3
Professional services	4.6		6.3		5.2		6.6		5.5		5.3		5.5		5.5
Total cost of revenue	42.5		46.0		44.3		45.6		44.3		44.0		44.7		45.2
Gross profit	57.5		54.0		55.7		54.4		55.7		56.0		55.3		54.8
Operating expenses:
Selling, general and administrative	29.4		33.7		32.1		31.8		30.9		33.6		31.9		33.4
Research and development costs, net	15.4		12.4		14.9		13.6		14.7		14.4		15.0		14.6
Amortization of acquired intangible assets	2.0		0.8		2.1		0.7		1.5		2.1		1.5		2.1
Restructuring costs	0.2		—		1.2		—		—		0.6		—		1.8
Total operating expenses	47.0		46.8		50.3		46.1		47.1		50.6		48.4		52.0
Income from operations	10.5		7.2		5.4		8.2		8.5		5.3		6.9		2.8
Interest income	—		0.1		—		0.1
Interest expense	(0.5	)	—		(0.6	)	—		(0.6	)	(0.6	)	(0.6	)	(0.7	)
Other expense, net	—		—		—		—
Other income (expense), net									—		—		—		(0.1	)
Income before provision for income taxes	10.0		7.2		4.7		8.3		7.9		4.6		6.3		2.0
Provision for income taxes	1.8		1.0		1.0		2.3		1.9		1.5		1.8		0.6
Net income	8.2	%	6.2	%	3.7	%	6.0	%	6.1	%	3.1	%	4.5	%	1.3	%

Revenues

The following table presents our consolidated revenues for the three and ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and 2015~~ (in thousands):


	Three Months Ended December 31,				Nine Months Ended December 31,				Three Months Ended September 30,				Six Months Ended September 30,
	2016		2015		2016		2015		2017		2016		2017		2016
Revenues:
Software license and hardware	$	16,995	$	16,150	$	48,966	$	52,026	$	14,267	$	17,182	$	27,067	$	31,971
Software related subscription services	22,546		11,705		63,911		36,388		24,988		21,490		48,894		41,365
Total software, hardware and related	39,541		27,855		112,877		88,414		39,255		38,672		75,961		73,336

Support and maintenance	39,924		39,519		116,905		125,408		41,693		38,974		82,809		76,981
Revenue cycle management and related services	20,048		21,594		62,037		62,630		21,002		20,936		42,405		41,989
Electronic data interchange and data services	21,790		20,643		65,527		61,413		22,998		21,613		46,310		43,737
Professional services	6,565		7,421		19,893		26,700		7,659		6,971		16,044		13,328
Total revenues	$	127,868	$	117,032	$	377,239	$	364,565	$	132,607	$	127,166	$	263,529	$	249,371

We generate revenue from sales of licensing rights and subscriptions to our software products, hardware and third party software products, support and maintenance services, revenue cycle management and related services ("RCM"), electronic data interchange and data services (“EDI”), and professional services, such as implementation, training, and consulting performed for clients who use our products.

Consolidated revenue for the three months ended ~~December 31, 2016~~September 30, 2017 increased ~~$10.8~~$5.4 million compared to the prior year ~~period,~~due to increases across each of our revenue streams, except software license and hardware. Software related subscription services increased $3.5 million, which was driven ~~primarily~~ by ~~subscription~~sales associated with the acquisition of Entrada in April 2017 and higher sales of ~~the~~our MediTouch® cloud-based ~~system acquired from HealthFusion~~subscriptions and our interoperability and patient portal offerings as we continue to expand our client base. The $2.7 million increase in ~~January 2016~~support and maintenance is primarily due to lower ~~level of~~ sales credits in the current year, addition of new customers, and ~~related reserves, which were partially~~annual increases to support and maintenance fees that are generally tied to changes in the Consumer Price Index (CPI). The $0.7 million increase in professional services is mostly associated with the acquisition of Entrada in April 2017, offset by lower ~~RCM revenue~~sales of professional services due to lower ~~net new bookings.~~

Consolidated revenue for the nine months ended December 31, 2016 increased $12.7 million compared to the prior year period as a result of $27.5 million higher subscriptions related mostly to sales of the MediTouch® cloud-based system, partially offset by lower software license and hardware revenue, lower professional services revenue, and lower support and maintenance revenue. The decline in software license and hardware revenue was mostly caused by a shift in market dynamics toward cloud-based solutions and away from perpetual license arrangements, which has also resulted in lowerclient demand for our ~~professional services, including~~core software products and related implementation, training, and consulting services. ~~The decline in support and maintenance is due primarily to the disposition of the former Hospital Solutions Division in October 2015 and net attrition in products sold with accompanying maintenance.~~

~~RCM revenue decreased $1.5 million and $0.6 million for the three and nine months ended December 31, 2016 and 2015, respectively, due to lower net new bookings.~~ EDI revenue increased ~~$1.1~~$1.4 million, ~~and $4.1 million for the three and nine months ended December 31, 2016 and 2015, respectively, due~~which was primarily related to higher EDI services sold with our MediTouch® cloud-based solutions, addition of new clients, and further penetration of our existing client base. The $2.9 million decline in software license and hardware reflects the increasingly saturated end-market for electronic health records software.

Consolidated revenue for the six months ended September 30, 2017 increased $14.2 million compared to the prior year due to increases across each of our revenue streams, except software license and hardware. Software related subscription services increased $7.5 million, which was driven by sales associated with the acquisition of Entrada in April 2017 and higher sales of our MediTouch® cloud-based subscriptions and our interoperability, patient portal, and QSIDental Web offerings as we continue to expand our client base. The $5.8 million increase in support and maintenance is primarily due to lower sales credits in the current year, addition of new customers, and annual increases to support and maintenance fees that are generally tied to changes in the Consumer Price Index (CPI). The $2.7 million increase in professional services is mostly associated with the acquisition of Entrada in April 2017, offset by lower sales of professional services due to lower client demand for our core software products and related implementation, training, and consulting services. EDI revenue increased $2.6 million, which was primarily related to higher EDI services sold with our MediTouch® cloud-based solutions, addition of new clients, and further penetration of our existing client base. RCM services revenue increased $0.4 million from the addition of new clients and organic growth achieved through cross selling and ramping up of RCM services provided to our existing clients, offset by customer attrition. The $4.9 million decline in software license and hardware reflects the increasingly saturated end-market for electronic health records software.

Recurring service revenue, consisting of software related subscription services, support and maintenance, RCM, and EDI, represented ~~81.6%~~83% and ~~79.9%~~81% of total revenue for the three months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively. For the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ recurring service revenue, represented ~~81.7%~~84% and ~~78.4%~~82%, respectively, of total revenue.

~~We expect~~Our goals include further enhancement of our existing products, including expansion of our software and service offerings that support pay-for-performance initiatives around accountable care organizations, bringing greater ease of use and intuitiveness to ~~benefit from the growth~~our software products, enhancing our managed cloud and hosting services to lower our clients' total cost of a replacement market driven by an expected consolidation of electronic health records vendors. We also anticipate the creation of new opportunities in connection with the evolution of healthcare from a fee-for-services reimbursement model to a pay-for-performance model around the management of patient populations. Our acquisitions of Gennius and Mirth provided us with new products and services around population health, collaborative care management,ownership, expanding our interoperability and enterprise analytics capabilities, and further development and enhancements of our portfolio of specialty focused templates within our electronic health records software.

We intend to remain at the forefront of upcoming new regulatory requirements, including meaningful use requirements for stimulus payments and recent healthcare reform that is driving the transition towards pay-for-performance, value-based reimbursement models. We believe that the expanded requirements for continued eligibility for incentive payments under meaningful use rules will result in an expanded replacement market for electronic health records software. We also intend to continue selling additional software and services to existing clients, expanding penetration of connectivity and other services to new and existing clients, and capitalizing on growth and cross selling opportunities. We continue to expand our client base and cloud-based solution capabilities in the ambulatory market to meet the needs of practices of increasing size and complexity, and focus our strategy on accountable care organizations around interoperability, patient engagements, population health and collaborative care management, and enterprise analytics. Our software and service offerings offer clients a full suite of cloud-based solutions that better enable our clients to focus on care delivery. We believe we are well-positioned within the evolving healthcare market to deliver products and services that address ~~these market dynamics.~~ the growing importance of quality collaborative care and shift from fee-for-service to value-based, pay-for-performance care. We also believe that a significant opportunity exists to continue cross selling RCM services to our existing clients as the portion of existing clients who are using RCM services is approximately 10%. We are actively pursuing efforts to achieve faster growth from expanded efforts to leverage our existing sales force towards selling RCM services. We also believe that ongoing increases in the complexity of medical billing and collections processes, including the migration to value-based reimbursement models, will create additional opportunities.

While it remains difficult to assess the relative impact or the timing of positive and negative trends affecting the aforementioned market opportunities, we believe we are well positioned to remain a leader in serving the evolving market needs for healthcare information technology.

We believe that our operating results are attributed to a strong brand name and reputation within the marketplace for healthcare information technology software and services and investments in sales and marketing activities, including new marketing campaigns, Internet advertising investments, tradeshow attendance and other expanded advertising and marketing expenditures.

Gross Profit

The following table presents our consolidated cost of revenue and gross profit for the three and ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and 2015~~ (in thousands):


	Three Months Ended December 31,						Nine Months Ended December 31,						Three Months Ended September 30,						Six Months Ended September 30,
	2016			2015			2016			2015			2017			2016			2017			2016
Total cost of revenue	$	54,352		$	53,785		$	167,164		$	166,360		$	58,755		$	55,997		$	117,924		$	112,812
Gross profit	73,516			63,247			210,075			198,205			73,852			71,169			145,605			136,559
Gross margin %	57.5		%	54.0		%	55.7		%	54.4		%	55.7		%	56.0		%	55.3		%	54.8		%

Cost of revenue consists primarily of compensation expense, including share-based compensation, for personnel that deliver our products and services. Cost of revenue also includes amortization of capitalized software costs and acquired technology, third party consultant and outsourcing costs, costs associated with our EDI business partners and clearinghouses, hosting service costs, third party software costs and royalties, and other costs directly associated with delivering our products and services. Refer to Note 5, "Intangible Assets" and Note 6, "Capitalized Software Costs" of our notes to consolidated financial statements included elsewhere in this Report for additional information on current period amortization of capitalized software costs and acquired technology and an estimate of future expected amortization.

Share-based compensation expense included in cost of revenue was ~~$0.1~~$0.3 million and ~~$0.1~~$0.2 million for the three months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015, respectively,~~ and is included in the amounts in the table above. Share-based compensation expense included in cost of revenue was ~~$0.5~~$0.4 million and $0.3 million for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015, respectively,~~ and is included in the amounts in the table above.

Gross profit for the three months ended ~~December 31, 2016~~September 30, 2017 increased ~~$10.3~~$2.7 million compared to the prior year period due primarily to $5.4 million higher revenues as discussed above, ~~and a lower level of sales credits and related reserves, which were~~ offset by a ~~$0.6~~$2.8 million increase in cost of revenue. ~~Cost~~Gross profit for the six months ended September 30, 2017 increased $9.0 million compared to the prior year period due primarily to $14.2 million higher revenues as discussed above, offset by a $5.1 million increase in cost of revenue. The increase in cost of revenue ~~increased due~~for both the three and six months ended September 30, 2017 compared to the prior year period is the result of higher costs associated with the acquisition of Entrada in April 2017, higher amortization of the software technology intangible asset acquired from ~~HealthFusion,~~Entrada, and higher personnel costs associated with delivering support and maintenance and RCM services, partially offset by lower amortization of previously capitalized software development ~~costs and lower payroll costs associated with delivering support and maintenance and professional services.~~cost. The gross margin percentage ~~increased to 57.5%~~remained consistent for both the three and six months ended ~~December 31, 2016 compared to 54.0% in the prior year period.~~

~~Gross profit for the nine months ended December 31, 2016 increased $11.9 million~~September 30, 2017 compared to the prior year period due also to higher revenues as discussed above, offset by a $0.8 million increase in cost of revenue. Cost of revenue increased due to amortization of the software technology intangible asset acquired from HealthFusion, partially offset by lower payroll costs associated with delivering support and maintenance and professional services. The gross margin percentage increased to 55.7% for the nine months ended December 31, 2016 compared to 54.4% in the prior year period.

Selling, General and Administrative Expense

The following table presents our consolidated selling, general and administrative expense for the three and ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and 2015~~ (in thousands):


	Three Months Ended December 31,						Nine Months Ended December 31,						Three Months Ended September 30,						Six Months Ended September 30,
	2016			2015			2016			2015			2017			2016			2017			2016
Selling, general and administrative	$	37,542		$	39,395		$	120,913		$	115,962		$	40,977		$	42,790		$	83,954		$	83,371
Selling, general and administrative, as a percentage of revenue	29.4		%	33.7		%	32.1		%	31.8		%	30.9		%	33.6		%	31.9		%	33.4		%

Selling, general and administrative expense consist of compensation expense, including share-based compensation, for management and administrative personnel, selling and marketing expense, facilities costs, depreciation, professional service fees, including legal, consulting, and accounting services, acquisition and transaction-related costs, and other general corporate and administrative expenses.

Share-based compensation expense included in selling, general and administrative expenses was ~~$1.6~~$2.3 million and ~~$0.6~~$1.4 million for the three months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively, and is included in the amounts in the table above. Share-based compensation expense included in selling, general and administrative expenses was ~~$4.0~~$3.8 million and ~~$1.7~~$2.4 million for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively, and is included in the amounts ~~in the table~~ above.

Selling, general and administrative expenses decreased ~~$1.9~~$1.8 million for the three months ended ~~December 31, 2016~~September 30, 2017 compared to the prior year ~~period primarily because we incurred $3.7~~due to $3.0 million of ~~acquisition-related costs~~fair value adjustments related to the ~~acquisition of~~ HealthFusion contingent consideration recorded in the prior year period, a $1.8 million loss on the disposition of the former Hospital Solutions Division in the prior year period, and recorded a current period benefit of $2.0 million related to fair value adjustments of the HealthFusion contingent

~~consideration, which were partially~~ offset by higher ~~legal expense related shareholder litigation~~incremental costs associated with Entrada acquired in April 2017 and ~~additional selling, general and administrative~~an increase in bad debt expense associated with ~~the acquisition of HealthFusion.~~our continued efforts to resolve aged customer receivable balances.

Selling, general and administrative expenses increased ~~$5.0~~$0.6 million for the ~~nine~~six months ended ~~December 31, 2016~~September 30, 2017 compared to the prior year period primarily due to ~~$3.4~~higher incremental costs associated with Entrada acquired in April 2017, an increase in bad debt expense associated with our continued efforts to resolve aged customer receivable balances, and higher consulting costs associated with our assessment and implementation of the new revenue standard (ASC 606, Revenue From Contracts With Customers), including implementation of a new accounting system module, offset by $5.4 million of fair value adjustments ofrelated to the HealthFusion contingent consideration recorded in the current period, higher legal expense related shareholder litigation, and additional selling, general and administrative expense associated with the acquisition of HealthFusion, partially offset by lower payroll costs associated with the corporate restructuring plan (refer to Note 15, "Restructuring Plan" of our notes to consolidated financial statements included elsewhere in this Report for additional information) and the disposition of the Hospital Solutions Division in October 2015.prior year period.

Research and Development Costs, net

The following table presents our consolidated net research and development costs, capitalized software costs, and gross expenditures prior to capitalization, for the three and ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and 2015~~ (in thousands):


	Three Months Ended December 31,						Nine Months Ended December 31,						Three Months Ended September 30,						Six Months Ended September 30,
	2016			2015			2016			2015			2017			2016			2017			2016
Gross expenditures	$	20,766		$	19,435		$	62,601		$	61,188		$	23,903		$	20,663		$	49,140		$	41,835
Capitalized software costs	(1,052		)	(4,917		)	(6,371		)	(11,604		)	(4,376		)	(2,371		)	(9,624		)	(5,319		)
Research and development costs, net	$	19,714		$	14,518		$	56,230		$	49,584		$	19,527		$	18,292		$	39,516		$	36,516

Research and development costs, as a percentage of revenue	15.4		%	12.4		%	14.9		%	13.6		%	14.7		%	14.4		%	15.0		%	14.6		%
Capitalized software costs as a percentage of gross expenditures	5.1		%	25.3		%	10.2		%	19.0		%	18.3		%	11.5		%	19.6		%	12.7		%

Gross research and development expenditures, including costs expensed and costs capitalized, consist of compensation expense, including share-based compensation for research and development personnel, certain third-party consultant fees, software maintenance costs, and other costs related to new product development and enhancement to our existing products. We intend to continue to invest heavily in research and development expenses as we continue to bring additional functionality and features to the medical community and develop a new integrated inpatient and outpatient, web-based software platform.

The capitalization of software development costs results in a reduction to our reported net research and development costs. Our software capitalization rate, or capitalized software costs as a percentage of gross expenditures, has varied historically and may continue to vary based on the nature and status of specific projects and initiatives in progress. Although changes in software capitalization rates have no impact on our overall cash flows, it results in fluctuations in the amount of software development costs being expensed up front and the amount of net research and development costs reported in our consolidated statement of net income and comprehensive income.

Share-based compensation expense included in research and development costs was ~~$0.3~~$0.5 million and ~~$0.1~~$0.3 million for the three months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively, and is included in the amounts in the table above. Share-based compensation expense included in research and development costs was ~~$0.7~~$0.9 million and ~~$0.3~~$0.4 million for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016, ~~and 2015,~~ respectively, and is included in the amounts ~~in the table~~ above.

Net research and development costs for the three months ended ~~December 31, 2016~~September 30, 2017 increased ~~$5.2~~$1.2 million compared to the prior year period, ~~primarily as~~which is due to a ~~result of a $3.9 million decline in capitalized software costs and a $1.3~~$3.2 million increase in our gross ~~expenditures.~~expenditures, offset by $2.0 million higher capitalization of software costs. Net research and development costs for the ~~nine~~six months ended ~~December 31, 2016~~September 30, 2017 increased ~~$6.6~~$3.0 million compared to the prior year, ~~period primarily as~~which is due to a ~~result of a $5.2 million decline in capitalized software costs and a $1.4~~$7.3 million increase in our gross ~~expenditures.~~expenditures, offset by $4.3 million higher capitalization of software costs. The increase in both gross expenditures and capitalization of software costs are related to the development of the next major versions of our core software products and enhancements to our existing products, for which we incurred a higher level of personnel and third party development costs. Additionally, the acquisition of ~~HealthFusion contributed $1.2 million~~Entrada in April 2017 and ~~$2.8 million of net~~an increase in our research and development ~~costs for~~headcount contributed to the ~~three and nine months ended December 31, 2016, respectively. Such increase was partially offset by lower~~increases in gross ~~expenditures from the discontinuation of the NextGen Now development project during the fourth quarter of fiscal 2016 and lower personnel costs associated with the restructuring plan.~~

~~The reduction in capitalized software costs for the three and nine months ended December 31, 2016 is due to a decline in the rate of the~~expenditures. Our software capitalization ~~compared~~rate fluctuates due to ~~the prior year periods, which reflects~~ differences in the nature and status of our projects and initiatives during a given ~~period that~~year, which affects the amount of development costs that may be ~~capitalized, the discontinuation of the NextGen Now development project, and the recent releases of the next major version of our core software products.~~

capitalized.

Amortization of Acquired Intangible Assets

The following table presents our amortization of acquired intangible assets for the three and ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and~~ ~~2015~~ (in thousands):

Three Months Ended December 31, Nine Months Ended December 31,
2016 2015 2016 2015
Amortization of acquired intangible assets $ 2,568
$ 897
$ 7,889
$ 2,692



	Three Months Ended September 30,				Six Months Ended September 30,
	2017		2016		2017		2016
Amortization of acquired intangible assets	$	2,012	$	2,617	$	4,059	$	5,321

Amortization of acquired intangible assets included in operating expense consist of the amortization related to our customer relationships, trade name, and contracts intangible assets acquired as part of our business combinations. Refer to Note 5, "Intangible Assets" of our notes to consolidated financial statements included elsewhere in this Report for an estimate of future expected amortization.

Amortization of acquired intangible assets for the three and ~~nine~~six months ended ~~December 31, 2016 increased $1.7~~September 30, 2017 declined $0.6 million and ~~$5.2~~$1.3 million, respectively, compared to ~~the~~ prior year ~~periods~~period due to ~~additional amortization of the customer relationships and trade name~~certain acquired intangible assets ~~related to~~being fully amortized during the ~~acquisition of HealthFusion. Refer to Note 5, "Business Combinations" of our notes to consolidated financial statements included elsewhere in this Report for additional information.~~year, partially offset by the incremental amortization associate with intangible assets acquired from Entrada and EagleDream.

Restructuring Costs

During the three and ~~nine~~six months ended ~~December 31,~~September 30, 2016, we recorded ~~$0.2~~$0.7 million and ~~$4.7~~$4.5 million, respectively, of restructuring costs within operating expenses in our consolidated statements of comprehensive income. The restructuring costs resulted from a restructuring plan that we announced in April 2016, and such costs consist primarily of payroll-related costs, such as severance, outplacement costs, and continuing healthcare coverage, associated with the involuntary separation of employees pursuant to a one-time benefit arrangement. The ~~remaining restructuring liability as of December 31, 2016 was not significant. The~~ restructuring plan ~~is expected to be~~was substantially complete by the end of fiscal ~~2017.~~

~~The~~2017, and thus we did not incur additional restructuring ~~is part of a three-phase plan initiated in fiscal year 2016 that was intended to better position our organization for future success. In~~costs during the ~~first phase, we restructured the organization to more effectively support the execution of our strategy. We believe that the restructuring will reduce our costs~~three and improve our financial performance. As we begin phase two of our reorganization, we will continue to build our infrastructure and enhance our healthcare information technology capabilities to drive future revenue growth. The third phase of the plan will consist of developing and marketing the services and solutions that we believe will accelerate revenue growth.

~~Refer to Note 15, "Restructuring Plan" of our notes to consolidated financial statements included elsewhere in this Report for additional information.~~six months ended September 30, 2017.

Interest and Other Income and Expense

The following table presents our interest expense for the three and ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and~~ ~~2015~~ (in thousands):


	Three Months Ended December 31,						Nine Months Ended December 31,						Three Months Ended September 30,						Six Months Ended September 30,
	2016			2015			2016			2015			2017			2016			2017			2016
Interest income	$	—		$	60		$	9		$	406		$	12		$	1		$	21		$	9
Interest expense	(629		)	(11		)	(2,445		)	(14		)	(840		)	(803		)	(1,517		)	(1,816		)
Other expense, net	(4		)	(43		)	(146		)	(147		)	15			(55		)	(7		)	(142		)

~~Interest income relates primarily to our marketable securities.~~ Interest expense relates to our revolving credit agreement that was entered into in January 2016 and the related amortization of deferred debt issuance costs. Refer to Note 7, “Line of Credit” of our notes to consolidated financial statements included elsewhere in this Report for additional information. ~~Other expense and income relates primarily to net realized gains and losses on~~

The fluctuations in our ~~marketable securities.~~

~~Interest expense for the three and nine months ended December 31, 2016 increased $0.6 million and $2.4 million, respectively, compared to the prior year. The increase is primarily related to the~~ interest expense ~~associated with~~is caused by changes in outstanding balances under our revolving credit agreement in the current year compared to prior year. As of September 30, 2017, we had $55.0 million in outstanding balances under the revolving

credit agreement, compared to an outstanding balance of $15.0 million as of March 31, 2017 and ~~the amortization~~$48.0 million as of ~~deferred debt issuance costs. As of December 31, 2016, we had $25.0 million in outstanding loans under the revolving credit agreement.~~

September 30, 2016. All other fluctuations in interest and other income and expense are not deemed significant.

Provision for Income Taxes

The following table presents our provision for income taxes for the three and ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and~~ ~~2015~~ (in thousands):


	Three Months Ended December 31,						Nine Months Ended December 31,						Three Months Ended September 30,						Six Months Ended September 30,
	2016			2015			2016			2015			2017			2016			2017			2016
Provision for income taxes	$	2,342		$	1,141		$	3,950		$	8,233		$	2,493		$	1,925		$	4,647		$	1,608
Effective tax rate	18.3		%	13.5		%	22.2		%	27.3		%	23.7		%	32.6		%	28.0		%	32.5		%

The effective rate for the three months ended December 31, 2016 increased compared to the prior year period primarily due to the impact of lower qualifying production activity deductions in the current period, certain non-deductible acquisition-related costs, and a discrete valuation allowance, offset by federal and state research and development credit and other discrete adjustments.

~~The effective rate for the nine months ended December 31, 2016~~September 30, 2017 decreased compared to the prior year period primarily due to a favorable ~~discrete adjustments for federal~~decline in the amount of certain non-deductible acquisition related costs and ~~state research and development credit, offset by non-deductible acquisition-related costs, lower qualifying production activity deductions in~~ the current period reduction in state taxes.

The effective rate for the six months ended September 30, 2017 decreased compared to the prior year period primarily due to a favorable decline in the amount of certain non-deductible acquisition related costs, the current period reduction in state taxes and ~~other discrete adjustments.~~the impact of excess tax deficiencies from share-based compensation recorded in the period.

Net Income

The following table presents our net income (in thousands) and net income per share and for the three and ~~nine~~six months ended ~~December 31, 2016~~September 30, 2017 and ~~2015~~:2016:


	Three Months Ended December 31,				Nine Months Ended December 31,				Three Months Ended September 30,				Six Months Ended September 30,
	2016		2015		2016		2015		2017		2016		2017		2016
Net income	$	10,486	$	7,302	$	13,826	$	21,979	$	8,030	$	3,987	$	11,926	$	3,340
Net income per share:
Basic	$	0.17	$	0.12	$	0.22	$	0.36	$	0.13	$	0.06	$	0.19	$	0.05
Diluted	$	0.17	$	0.12	$	0.22	$	0.36	$	0.13	$	0.06	$	0.19	$	0.05

As a result of the foregoing changes in revenue and expense, net income for the three and ~~nine~~six months ended ~~December 31, 2016 decreased $3.2~~September 30, 2017 increased $4.0 million and ~~$8.2~~$8.6 million, respectively, compared to the prior year period.

~~Operating Segment Information~~

Effective July 1, 2016, we revised our reportable operating segments. As part of our ongoing reorganization efforts, we refined the measurement of our segment data to better reflect our current internal organizational structure whereby certain functions that formerly existed within each individual operating segment have changed. Our operating segments now consist of the Software and Related Solutions segment and the RCM and Related Services segment, which is consistent with the disaggregated financial information used and evaluated by our chief operating decision maker (consisting of our Chief Executive Officer) to assess performance and make decisions about the allocation of resources. Revenue and gross profit are the key measures of segment profitability used by our chief operating decision maker to measure segment operating performance and to make key business decisions. The revenues and gross profit of each segment are derived from distinct product and services within each segment. The Software and Related Solutions segment aggregates the revenues and gross profit of our software-related products and services, including software license and hardware, software-related subscription services, support and maintenance, EDI and data services, and certain professional services, such as implementation, training, and consulting. The RCM and Related Services segment aggregates the revenues and gross profit of our RCM services and certain related ancillary service offerings.

Three Months Ended December 31, Nine Months Ended December 31,
2016 2015 2016 2015
Revenue:
Software and Related Solutions $ 106,958
$ 93,927
$ 312,854
$ 291,783
RCM and Related Services 20,910
22,486
64,385
65,313
Hospital Solutions⁽¹⁾
—
619
—
7,469
Consolidated revenue $ 127,868
$ 117,032
$ 377,239
$ 364,565

Gross profit:
Software and Related Solutions $ 71,252
$ 58,949
$ 204,414
$ 184,982
RCM and Related Services 7,077
7,769
21,337
20,792
Hospital Solutions⁽¹⁾
—
(69 ) —
2,569
Unallocated cost of revenue⁽²⁾
(4,813 ) (3,402 ) (15,676 ) (10,138 )
Consolidated gross profit $ 73,516
$ 63,247
$ 210,075
$ 198,205

⁽²⁾ ~~Consists of amortization of acquired software technology and amortization of capitalized software costs not allocated to the operating segments for the purposes of measuring performance.~~

~~Software and Related Solutions~~

Software and Related Solutions revenue for the three months ended December 31, 2016 increased $13.0 million and gross profit increased $12.3 million compared to the prior year period. Software and Related Solutions revenue for the nine months ended December 31, 2016 increased $21.1 million and gross profit increased $19.4 million compared to the prior year period.

The increase in revenues for the three months ended December 31, 2016 was driven by an increase in our software related subscription services attributed mostly to the acquisition of HealthFusion in January 2016 and an increase in EDI revenue from the addition of new clients and further penetration of our existing client base, which were partially offset by a decline in professional services revenue, resulting from a recent decline in demand for our core software products and related services.

The increase in revenues for the nine months ended December 31, 2016 was also driven by an increase in our software related subscription services attributed mostly to the acquisition of HealthFusion in January 2016 and an increase in EDI revenue from the addition of new clients and further penetration of our existing client base, which were partially offset by a decline in software license and hardware and professional services revenue, resulting from a shift in market dynamics toward cloud-based solutions and away from perpetual license arrangements, resulting in lower client demand for our core software products and related support and maintenance, implementation, training, and consulting services.

The increase in gross profit for the three and nine months ended December 31, 2016 is due primarily to the aforementioned increases in revenue, which were offset by an increase in cost of revenue. Cost of revenue increased due to amortization of the software technology intangible asset acquired from HealthFusion, partially offset by lower amortization of previously capitalized software development costs and lower payroll costs associated with delivering support and maintenance and professional services. Gross profit for the three months ended December 31, 2016 was also positively impacted due to a lower level of sales credits and related reserves compared to the prior year period.

Our goals for Software and Related Solutions include further enhancement of our existing products, including expansion of our software and service offerings that support pay-for-performance initiatives around accountable care organizations, bringing greater ease of use and intuitiveness to our software products, enhancing our managed cloud and hosting services to lower our clients' total cost of ownership, expanding our interoperability and enterprise analytics capabilities, and further development and enhancements of our portfolio of specialty focused templates within our electronic health records software. We intend to remain at the forefront of upcoming new regulatory requirements, including meaningful use requirements for stimulus payments and recent healthcare reform that is driving the transition towards pay-for-performance, value-based reimbursement models. We believe that the expanded requirements for continued eligibility for incentive payments under meaningful use rules will result in an expanded

replacement market for electronic health records software. We also intend to continue selling additional software and services to existing clients, expanding penetration of connectivity and other services to new and existing clients, and capitalizing on growth and cross selling opportunities within RCM and Related Services. Our acquisition of HealthFusion will allow us expand our client base and cloud-based solution capabilities in the ambulatory market and meet the needs of practices of increasing size and complexity. Our acquisitions of Mirth and Gennius improve our competitiveness in the markets and provide new clients and expanded markets for Software and Related Solutions and also support our strategy to focus on accountable care organizations around interoperability, patient engagements, population health and collaborative care management, and enterprise analytics. We believe we are well-positioned within the evolving healthcare market to deliver products and services that address the growing importance of quality collaborative care and shift from fee-for-service to value-based, pay-for-performance care.

~~RCM and Related Services~~

RCM and Related Services revenue for the three months ended December 31, 2016 decreased $1.6 million compared to the prior period due to lower net new bookings. Gross profit for the three months ended December 31, 2016 decreased $0.7 million due to the decline in revenues, partially offset by a reduction in employee-related costs.

RCM and Related Services revenue for the nine months ended December 31, 2016 decreased $0.9 million compared to the prior year period due to lower net new bookings. Gross profit for the nine months ended December 31, 2016 increased $0.5 million due to lower employee related costs, partially offset by a decline in revenue.

We believe that a significant opportunity exists to continue cross selling RCM services to our existing clients. The portion of existing NextGen clients who are using RCM services is approximately 10%. We are actively pursuing efforts to achieve faster growth from expanded efforts to leverage our existing sales force towards selling RCM services. We also believe that ongoing increases in the complexity of medical billing and collections processes, including the migration to value-based reimbursement models, will create additional opportunities for RCM and Related Services.

Liquidity and Capital Resources

The following table presents selected financial statistics and information for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and 2015~~ (in thousands):


	Nine Months Ended December 31,				Six Months Ended September 30,
	2016		2015		2017		2016
Cash and cash equivalents and marketable securities	$	23,994	$	104,813
Unused portion of revolving credit agreement(1)	225,000		—
Cash and cash equivalents					$	26,553	$	26,246
Unused portion of revolving credit agreement⁽¹⁾					195,000		202,000
Total liquidity	$	248,994	$	104,813	$	221,553	$	228,246

Net income	$	13,826	$	21,979	$	11,926	$	3,340
Net cash provided by operating activities	$	81,423	$	27,292	$	38,094	$	56,385

_________________________

⁽¹⁾ As of ~~December 31, 2016,~~September 30, 2017, we had ~~our~~ outstanding loans of ~~$25.0~~$55.0 million under our $250.0 million revolving credit agreement.

Our principal sources of liquidity are our cash generated from operations, driven mostly by our net income and working capital management, our cash and cash equivalents, and ~~the Credit Agreement.~~our revolving credit agreement.

Cash and Cash Equivalents

As of ~~December 31, 2016,~~September 30, 2017, our cash and cash equivalents balance of ~~$24.0~~$26.6 million reflects ~~a $12.5~~an $11.1 million decrease compared to ~~$36.5~~$37.7 million ~~of cash, cash equivalents and marketable securities~~ as of March 31, ~~2016.~~2017. This decrease primarily reflects ~~$80.0~~$58.9 million of net cash paid for the acquisitions of Entrada and EagleDream, which were partially funded by $50.0 million of additional borrowings under our revolving credit agreement, offset by $10.0 million of principal ~~repayments on our revolving line~~repayments. Additionally, we paid $18.8 million to settle the contingent consideration liability related to the acquisition of ~~credit, partially offset by an increase in cash provided by operating activities as discussed further below, and payment of dividends in the prior year period.~~

In January 2016, we entered into a $250.0 million revolving credit agreement (the "Credit Agreement") with JPMorgan Chase Bank, N.A., as administrative agent, U.S. Bank National Association, as syndication agent, and certain other lenders.HealthFusion. Our outstanding loans under ~~the Credit Agreement~~our revolving credit agreement was ~~$25.0~~$55.0 million as of ~~December 31, 2016.~~

September 30, 2017.

We may continue to use a portion of our funds as well as available financing from ~~the Credit Agreement~~our revolving credit agreement for future acquisitions or other similar business activities, although the specific timing and amount of funds to be used is not currently determinable. ~~Our principal sources of liquidity are our cash and cash equivalents, the Credit Agreement, as well as our cash generated from operations.~~ We intend to expend some of our available funds for the development of products complementary to our existing product line as well as new versions of certain of our products. These developments are intended to take advantage of more powerful technologies and to increase the integration of our products.

Our investment policy is determined by our Board of Directors. Excess cash, if any, may be invested in very liquid short term assets including tax exempt and taxable money market funds, certificates of deposit and short term municipal bonds with average maturities of 365 days or less at the time of purchase. Our Board of Directors continues to review alternate uses for our cash including an expansion of our investment policy and other items. Any or all of these programs could significantly impact our investment income in future periods.

We believe that our cash and cash equivalents ~~and marketable securities~~ on hand at ~~December 31, 2016,~~September 30, 2017, together with our cash flows from operations and liquidity provided by ~~the Credit Agreement,~~our revolving credit agreement, will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months.

Cash Flows from Operating Activities

The following table summarizes our consolidated statements of cash flows for the ~~nine~~six months ended ~~December 31,~~September 30, 2017 and 2016 ~~and 2015~~ (in thousands):


	Nine Months Ended December 31,						Six Months Ended September 30,
	2016			2015			2017			2016
Net income	$	13,826		$	21,979		$	11,926		$	3,340
Non-cash expenses	45,613			27,426			29,195			34,097
Cash from net income, as adjusted	$	59,439		$	49,405		$	41,121		$	37,437

Change in deferred revenue	$	(8,195	)	$	(10,320	)
Change in accounts receivable	16,005			11,313
Change in other assets and liabilities	14,174			(23,106		)	(3,027		)	18,948
Net cash provided by operating activities	$	81,423		$	27,292		$	38,094		$	56,385

For the ~~nine~~six months ended ~~December 31, 2016,~~September 30, 2017, cash provided by operating activities ~~increased $54.1~~decreased $18.3 million compared to the prior year ~~period.~~period primarily due to higher cash used related to changes in other assets and liabilities because the prior year period benefited from decreases in accounts receivable and income taxes receivable. Cash from net income, as adjusted to exclude non-cash expenses increased $3.7 million due to a $8.6 million increase in net income, offset by a $4.9 million decrease in non-cash expenses. Refer to the "Net Income" section above for additional details regarding the fluctuations in net income. The ~~increase~~decrease in non-cash expenses is primarily due to a $36.5 million increase in cash flows from changes in income taxes, $10.0 million higher net income, as adjusted for non-cash expenses, and a $6.8 million increase from changes in accounts receivable and deferred revenue. Non-cash expenses increasedthe fair value adjustments related to ~~$45.6 million for~~ the ~~nine months ended December 31, 2016 compared to $27.4 million~~HealthFusion contingent consideration recorded in the prior year ~~primarily due to higher amortization of intangibles associated with the acquisition of HealthFusion and changes in the fair value of contingent consideration liabilities.~~period.

Cash Flows from Investing Activities

Net cash used in investing activities for the ~~nine~~six months ended ~~December 31, 2016~~September 30, 2017 was ~~$5.6~~$73.9 million compared with ~~$22.2~~$1.0 million of cash used in investing activities in the prior year period. The ~~$16.6 million decrease~~increase in net cash used in investing activities is primarily due to $58.9 million net cash paid for the acquisitions of Entrada and EagleDream, $9.3 million ~~of cash~~lower proceeds from ~~the~~ sales of marketable securities, ~~in the nine months ended December 31, 2016 compared to $0.7~~and $4.3 million ~~of net purchases in the prior year period, a $5.2 million decrease~~increase in additions to capitalized software costs associated with the development of new products and ~~a $1.7~~enhancement of existing products, and $0.4 million ~~decrease in~~higher additions to equipment and improvements.

Cash Flows from Financing Activities

Net cash ~~used in~~provided by financing activities for the ~~nine~~six months ended ~~December 31, 2016~~September 30, 2017 was ~~$79.0~~$24.7 million compared with ~~$31.4~~$56.3 million cash used by financing activities in the prior year period. The increase in cash ~~used~~provided in financing activities relates to ~~$80.0~~$40.0 million of net cash provided by our revolving credit agreement, including $50.0 million of additional borrowings and $10.0 million of principal repayments, ~~on our revolving line~~and $4.3 million proceeds from the issuance of ~~credit in the current year period, partially~~shares under employee stock plans, offset by ~~$32.1~~$18.8 million paid to settle the contingent consideration liability related to the acquisition of HealthFusion, compared to $57.0 million in ~~dividends paid to shareholders~~principal repayments during the prior year period.

Contractual Obligations

The following table summarizes our significant contractual obligations at ~~December 31, 2016~~September 30, 2017 and the effect that such obligations are expected to have on our liquidity and cash in future periods (in thousands):


			For the year ended March 31,														For the year ended March 31,
Contractual Obligations	Total		2017 (remaining three months)		2018		2019		2020		2021		2022 and beyond		Total		2018 (remaining six months)		2019		2020		2021		2022		2023 and beyond
Operating lease obligations ⁽¹⁾	$	71,136	$	2,816	$	10,980	$	10,116	$	9,222	$	9,226	$	28,776	$	58,040	$	4,331	$	8,759	$	8,437	$	8,407	$	8,120	$	19,986
Line of credit obligations	25,000		—		—		—		—		25,000		—
Contingent consideration and other acquisition related liabilities	18,567		18,567		—		—		—		—		—
Remaining lease obligations for vacated properties ⁽¹⁾															5,309		1,197		1,413		794		816		551		538
Line of credit obligations (Note 7)															55,000		—		—		—		55,000		—		—
Purchase commitments ⁽²⁾															$	2,863	$	313	$	1,250	$	1,300	$	—	$	—	$	—
Total	$	114,703	$	21,383	$	10,980	$	10,116	$	9,222	$	34,226	$	28,776	$	121,212	$	5,841	$	11,422	$	10,531	$	64,223	$	8,671	$	20,524

_________________________

⁽¹⁾ ~~Operating~~Remaining lease obligations for vacated properties relates to remaining lease obligations at certain locations, including Austin, Solana Beach, Costa Mesa, and a portion of Horsham, that we have vacated and are actively marketing the locations for sublease as part of our reorganization efforts. Total obligations have not been reduced by projected sublease rentals or by minimum sublease rentals of ~~$1.9~~$1.1 million due in future periods under ~~our~~ non-cancelable subleases.

⁽²⁾Purchase commitments relates to payments due under certain non-cancelable agreements to purchase goods and services.

The deferred compensation liability as of ~~December 31, 2016~~September 30, 2017 was ~~$6.7~~$6.4 million, which is not included in the table above as the timing of future benefit payments to employees is not determinable.

The uncertain tax position liability as of ~~December 31, 2016~~September 30, 2017 was ~~$4.7~~$5.3 million, which is not included in the table above as the timing of expected payments is not determinable.

New Accounting Pronouncements

Refer to Note 1, “Summary of Significant Accounting Policies” of our notes to consolidated financial statements included elsewhere in this Report for a discussion of new accounting standards.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As of ~~December 31, 2016,~~September 30, 2017, we were subject to minimal market risk on our cash and cash equivalents as we maintained our balances in very liquid funds with maturities of 90 days or less at the time of purchase.

As of ~~December 31, 2016,~~September 30, 2017, we had ~~$25.0~~$55.0 million in outstanding loans under our revolving credit agreement. The revolving loans under the agreement bear interest at our option of either, (a) a base rate based on the highest of (i) the rate of interest per annum publicly announced from time to time by JPMorgan Chase Bank, N.A., as its prime rate, (ii) the greater of (A) the federal funds effective rate and (B) the overnight bank funding rate (as determined by the Federal Reserve Bank of New York) plus 0.50% and (iii) the one-month British Bankers Association London Interbank Offered Rate ("LIBOR") plus 1.00%) plus an applicable margin based on our leverage ratio from time to time, ranging from 0.50% to 1.50%, or (b) a LIBOR-based rate (subject to a floor of 0.00%) plus an applicable margin based on our leverage ratio from time to time, ranging from 1.50% to 2.50%. Accordingly, we are exposed to interest rate risk, primarily changes in LIBOR, due to our loans under the revolving credit agreement. A one hundred basis point (1.00%) change in the interest rate on our outstanding loans as of ~~December 31, 2016~~September 30, 2017 would result in a corresponding change in our annual interest expense of approximately ~~$0.3~~$0.6 million. Refer to Note 7, “Line of Credit” of our notes to consolidated financial statements included elsewhere in this Report for additional information.

As of ~~December 31, 2016,~~September 30, 2017, we had international operations that exposed us to the risk of fluctuations in foreign currency exchange rates against the U.S. dollar. However, the impact of foreign currency fluctuations has not been material to our financial position or operating results.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively) have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Security Exchange Act of 1934, as amended, the "Exchange Act") as of ~~December 31, 2016,~~September 30, 2017, the end of the period covered by this Quarterly Report on Form 10-Q (the “Evaluation Date”). They have concluded that, as of the Evaluation Date, these disclosure controls and procedures were effective to ensure that material information relating to the Company and its consolidated subsidiaries would be made known to them by others within those entities and would be disclosed on a timely basis. The Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are designed, and are effective, to give reasonable assurance that the information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the rules and forms of the Securities and Exchange Commission. They have also concluded that ~~the~~ our disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports that are filed or submitted under the Exchange Act are accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the quarter ended ~~December 31, 2016,~~September 30, 2017, there were no changes in our “internal control over financial reporting” (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

Hussein Litigation

On October 7, 2013, a complaint was filed against our Company and certain of our officers and directors in the Superior Court of the State of California for the County of Orange, captioned Ahmed D. Hussein v. Sheldon Razin, Steven Plochocki, Quality Systems, Inc. and Does 1-10, inclusive, No. 30-2013-00679600-CU-NP-CJC, by Ahmed Hussein, a former director and significant shareholder of our Company. We filed a demurrer to the complaint, which the Court granted on April 10, 2014. An amended complaint was filed on April 25, 2014. The amended complaint generally alleges fraud and deceit, constructive fraud, negligent misrepresentation and breach of fiduciary duty in connection with statements made to our shareholders regarding our financial condition and projected future performance. The amended complaint seeks actual damages, exemplary and punitive damages and costs. We filed a demurrer to the amended complaint. On July 29, 2014, the Court sustained the demurrer with respect to the breach of fiduciary duty claim, and overruled the demurrer with respect to the fraud and deceit claims. On August 28, 2014, we filed an answer and also filed a cross-complaint against ~~the plaintiff,~~Hussein, alleging that the plaintiff breached fiduciary duties owed to the Company, Mr. Razin and Mr. Plochocki. Mr. Razin and Mr. Plochocki have dismissed their claims against Hussein, leaving QSI as the sole plaintiff in the cross-complaint. On June 26, 2015, we filed a motion for summary judgment with respect to Hussein’s claims, which the Court granted on September 16, 2015, dismissing all of Hussein’s claims against us. On September 23, 2015, ~~the plaintiff~~Hussein filed an application for reconsideration of the Court's summary judgment order, which the Court denied. Hussein filed a renewed application for reconsideration of the Court’s summary judgment order ~~which~~on August 3, 2017. Argument on the ~~Court denied.~~ renewed application for reconsideration is scheduled for October 26, 2017.

On October 28, 2015, ~~the plaintiff~~May 9, 2016, and August 5, 2016, Hussein filed a motion for summary judgment, ~~seeking to dismiss our cross-complaint, which the Court denied on March 3, 2016. On May 9, 2016, the plaintiff filed a~~ motion for summary adjudication, ~~seeking to again dismiss our cross-complaint, which the Court denied on August 5, 2016. On August 5, 2016, the plaintiff filed a~~and motion for judgment on the pleadings, respectively, seeking to ~~again~~ dismiss our cross-complaint. The Court denied each motion. Trial on our cross-complaint ~~which~~began June 12, 2017. On July 26, 2017, the Court ~~denied~~issued a statement of decision granting Hussein’s motion for judgment on ~~September 2, 2016. Trial is set for April 10, 2017~~our cross-complaint. We believe the Court’s decision on ~~QSI’s cross-complaint.~~our cross-complaint was erroneous and we are evaluating a potential appeal. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

Federal Securities Class Action

On November 19, 2013, a putative class action complaint was filed on behalf of the shareholders of our Company other than the defendants against us and certain of our officers and directors in the United States District Court for the Central District of California by one of our shareholders. After the Court appointed lead plaintiffs and lead counsel for this action, and recaptioned the action In re Quality Systems, Inc. Securities Litigation, No. ~~8L13-cv-01818-CJC(JPRx),~~8:13-cv-01818-CJC-JPR, lead plaintiffs filed an amended complaint on April 7, 2014. The amended complaint, which is substantially similar to the litigation described above under the caption “Hussein Litigation,” generally alleges that statements made to our shareholders regarding our financial condition and projected future performance were false and misleading in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the individual defendants are liable for such statements because they are controlling persons under Section 20(a) of the Exchange Act. The complaint seeks compensatory damages, court costs and attorneys' fees. We filed a motion to dismiss the amended complaint on June 20, 2014, which the Court granted on October 20, 2014, dismissing the complaint with prejudice. Plaintiffs filed a motion for reconsideration of the Court's order, which the Court denied on January 5, 2015. On January 30, 2015, Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Ninth Circuit, captioned In re Quality Systems, Inc. Securities Litigation, No. 15-55173. ~~Plaintiffs filed their opening brief and we answered.~~ Oral argument was held on December 5, 2016. ~~The~~On July 28, 2017, the Ninth Circuit issued a decision reversing and remanding the District Court's ~~decision remains pending.~~order on our motion to dismiss. On September 5, 2017, we filed a petition for rehearing en banc, which was denied on September 29, 2017. We believe that the ~~plaintiffs’~~plaintiffs' claims are without merit and continue to defend against them ~~vigorously.~~vigorously, including by evaluating potential challenges to the Ninth Circuit decision. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

Shareholder Derivative Litigation

On January 24, 2014, a complaint was filed against our Company and certain of our officers and current and former directors in the United States District Court for the Central District of California, captioned Timothy J. Foss, derivatively on behalf of himself and all others similarly situated, vs. Craig A. Barbarosh, George H. Bristol, James C. Malone, Peter M. Neupert, Morris Panner, D. Russell Pflueger, Steven T. Plochocki, Sheldon Razin, Lance E. Rosenzweig and Quality Systems, Inc., No. SACV14-00110-DOC-JPPx, by Timothy J. Foss, a shareholder of ours. The complaint arises from the same allegations described above under the captions “Hussein Litigation” and “Federal Securities Class Action” and generally alleges breach of fiduciary duties, abuse of control and gross mismanagement by our directors, in addition to unjust enrichment and insider selling by individual directors. The complaint seeks compensatory damages, restitution and disgorgement of all profits, court costs, attorneys’ fees and implementation of enhanced corporate governance procedures. The parties have agreed to stay this litigation until the United States Court of Appeals for the Ninth Circuit issues a ruling on the pending appeal described above under the caption “Federal Securities Class ~~Action”.~~ Action,” and will meet and confer to discuss process going forward.

We believe that the plaintiff’s claims are without merit and intend to defend against them vigorously. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

In addition to the above, we have experienced legal claims by customers regarding product and contract disputes and from time to time, claims by other third parties asserting that we have infringed their intellectual property rights. We believe that these claims, including those filed by Mr. Hussein, the Deerfield Beach Police Pension Fund and the shareholder derivative action, are without merit and intend to defend against them vigorously; however, we could incur substantial costs and diversion of management resources even if we are ultimately successful in the defense of such claims. Litigation is inherently uncertain and always difficult to predict. We refer you to the discussion of infringement and litigation risks in our “Item 1A. Risk Factors” section of our Annual Report.

Other Regulatory Matters

In April 2017, we received a request for documents and information from the U.S. Attorney's Office for the District of Vermont pursuant to a Civil Investigative Demand (“CID”). The CID relates to an investigation concerning the certification we obtained for our software under the U.S. Department of Health and Human Services' Electronic Health Record Incentive Program. Given the highly-regulated nature of our industry, we may, from time to time, be subject to subpoenas, requests for information, or investigations from various government agencies. It is our practice to respond to such matters in a cooperative, thorough and timely manner. We are currently responding to this CID and intend to cooperate fully with the government. Requests and investigations of this nature may lead to the assertion of claims or the commencement of legal proceedings against us, as well as other material liabilities. In addition, our responses to the CID require time and effort, which can result in additional cost to us. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

ITEM 1A. RISK FACTORS.

Our business is subject to many risks and uncertainties, which may materially and adversely affect our future business, prospects, financial condition and results of operations. These risk factors are disclosed in “Item 1A. Risk Factors” in our Annual Report.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not Applicable

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.



Exhibit Number	Exhibit Description	Filed Herewith

10.1*10.1	~~Form of Change of Control Severance Agreement, entered into with the Company's named executive officers effective December 27, 2016.~~
10.2*	~~Form of Performance Stock Award Grant Notice and Performance/Restricted Stock Award Agreement for~~ Amended 2015 Equity Incentive Plan ~~entered into with~~(incorporated by reference from Exhibit 10.1 of the ~~Company's named executive officers effective December 29, 2016.~~registrant's Current Report on Form 8-K filed August 23, 2017).
10.3*10.2	Agreement and Plan of Merger, dated July 31, 2017, by and among Quality Systems, Inc., Peacock Merger Sub, Inc., EagleDream Health Inc. and Algimantas K. Chesonis (in the capacity of Securityholders' Representative) (incorporated by reference from Exhibit 2.1 of the registrant's Current Report on Form of Restricted Stock Award Grant Notice and Performance/Restricted Stock Award Agreement for 2015 Equity Incentive Plan, entered into with the Company's named executive officers effective December 29, 2016.8-K filed August 1, 2017).
31.1	Certification of Principal Executive Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	X
31.2	Certification of Principal Financial Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	X
32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	X
101.INS**	XBRL Instance
101.SCH**	XBRL Taxonomy Extension Schema
101.CAL**	XBRL Taxonomy Extension Calculation
101.DEF**	XBRL Taxonomy Extension Definition
101.LAB**	XBRL Taxonomy Extension Label
101.PRE**	XBRL Taxonomy Extension Presentation
* This exhibit is a management contract or a compensatory plan or arrangement, which were filed as Exhibits to the Company’s Current Report on Form 8-K filed January 3, 2017.
** XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of section 11 or 12 of the Securities and Exchange Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise is not subject to liability under these section.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



			QUALITY SYSTEMS, INC.
Date:	~~January 25,~~October 26, 2017	By:	/s/ John R. Frantz
			John R. Frantz
			Chief Executive Officer (Principal Executive Officer)

Date:	~~January 25,~~October 26, 2017	By:	/s/ James R. Arnold
			James R. Arnold
			Chief Financial Officer (Principal Financial Officer)

~~Date:~~	~~January 25, 2017~~	~~By:~~	~~/s/ John K. Stumpf~~
			~~John K. Stumpf~~
			~~Principal Accounting Officer~~

3837



	Total Liabilities
Balance at April 1, 2016	$	23,843
Settlement of contingent consideration related to Mirth	(9,273		)
Fair value adjustments	3,797
Transfer of HealthFusion contingent consideration to Level 2	(18,367		)
Balance at December 31, 2016	$	—



Initial purchase price	$	165,000
Contingent consideration	16,700
Preliminary working capital and other adjustments	1,349
Total preliminary purchase price	$	183,049



	January 4, 2016
Preliminary fair value of the net tangible assets acquired and liabilities assumed:
Acquired cash and cash equivalents	$	2,225
Accounts receivable, net	1,514
Prepaid expenses and other current assets	4,645
Equipment and improvements, net	767
Capitalized software costs, net	307
Other assets	700
Accounts payable	(1,085		)
Accrued compensation and related benefits	(533		)
Deferred revenue	(1,067		)
Deferred income taxes, net	(9,078		)
Other liabilities	(2,721		)
Total preliminary net tangible assets acquired and liabilities assumed	(4,326		)
Preliminary fair value of identifiable intangible assets acquired:
Software technology	42,500
Customer relationships	28,500
Trade name	4,000
Goodwill	112,375
Total preliminary identifiable intangible assets acquired	187,375
Total preliminary purchase price	$	183,049



	December 31, 2016		March 31, 2016
Software and Related Solutions	$	153,598	$	156,547
RCM and Related Services	32,290		32,290
Total goodwill	$	185,888	$	188,837